Jan 2024

CURRICULUM VITAE

Rhonda M. Cooper-DeHoff, Pharm D, MS, FACC, FAHA, FCCP

Address: Residence - 6303 NW 93rd Terrace
Gainesville, FL 32653

Office - Department of Pharmacotherapy and Translational Research
College of Pharmacy
University of Florida
PO Box 100486
Gainesville, FL 32610-0486

Email - dehoff@cop.ufl.edu

Telephone: Cell - (352) 359-2658

Place of Birth: Anaheim, California
Date of Birth: February 1, 1960
Citizenship: USA
Marital Status: Married

Present Positions: Associate Professor with Tenure
Department of Pharmacotherapy and Translational Research
College of Pharmacy

Joint Faculty Appointment in:
Division of Cardiovascular Medicine
Department of Medicine
College of Medicine

University of Florida

EDUCATION

2007	University of Florida	M.S. in Medical Science with a Concentration in Clinical Investigation
1986	University of California School of Pharmacy San Francisco, California	Doctor of Pharmacy
1982	University of California Revelle College San Diego, California	Gen. Biology B.A.

POST GRADUATE TRAINING

2005-2007	University of Florida College of Medicine, Gainesville, FL, Fellow in the Advanced Postgraduate Program in Clinical Investigation (APPCI), funded by the NIH Clinical Research Curriculum Award (K30)
2006	American Heart Association, Fellowship 32nd Ten-day Seminar on the Epidemiology and Prevention of Cardiovascular Disease
1986-1987	University of California, San Francisco, Residency in Clinical Pharmacy

BOARD CERTIFICATION

Licentiate in Pharmacy, California (inactive)
Licentiate in Pharmacy, Florida (current)

PROFESSIONAL POSITIONS

July 2012-Present	Associate Professor with Tenure University of Florida, College of Pharmacy Department of Pharmacotherapy and Translational Research
May 2014-2021	Associate Director, Center for Pharmacogenetics University of Florida, College of Pharmacy Department of Pharmacotherapy and Translational Research
Feb 2018-July 2019	Director, Graduate Program in Precision Medicine University of Florida Health Science Center
Mar 2009-June 2012	Associate Professor University of Florida, College of Pharmacy Department of Pharmacotherapy and Translational Research
July 2008-Feb 2009	Research Associate Professor University of Florida, College of Medicine Division of Cardiovascular Medicine
Sept 1999-June 2008	Research Assistant Professor University of Florida, College of Medicine Division of Cardiovascular Medicine
Sept 1999-Feb 2009	Associate Director, Clinical Trials Program University of Florida, College of Medicine Division of Cardiovascular Medicine Gainesville, FL
1997-2004	Director, INVEST Pharmacy Coordinating Center University of Florida, College of Medicine Division of Cardiology Gainesville, FL
1994-1997	Director, Pharmacy Practice Residency

Shands Hospital at the University of Florida
Gainesville, Florida

1987-1999 Coordinator, Investigational Drug Service
Shands Hospital at the University of Florida
Gainesville, Florida
Supervisor: Alan Knudsen, MS

AWARDS AND HONORS

2023 UF College of Pharmacy - Faculty Mentor of the Year
2022 Appointed Program Director for the inaugural CV Team Faculty Development Course, (live course) American College of Cardiology
2021 UF College of Pharmacy Faculty Advisor of the Year for Student Organization
2021 UF Cancer Center – Principal Investigator of the Year
2019 National Extension Association of Family & Consumer Sciences – 1st Place National Winner, Communications Internet Education Technology
2019 UF Research Foundation Professor 2019-2022 Award
2018 Teacher Service Incentive Award, University of Florida
2018 Award for Sustained Contributions, American Society of Health-System Pharmacists
2018 Phi Lambda Sigma Pharmacy Leadership Society Inductee
2017-2018 University of Florida Term Professorship Awardee
2016 Russell R. Miller Award, for substantial contributions to the literature, from the American College of Clinical Pharmacy
2015-2016 Faculty of the American College of Clinical Pharmacy Research Institute Mentored Research Investigator Training Program (MeRIT)
2015-2018 NHLBI Scientific Review Panel (Loan Repayment Program)
2015 Distinguished Investigator Award, American College of Clinical Pharmacy, Cardiology PRN
2015 Designated as a Master Mentor – 2014-2015 UF Mentor Academy
2015 Distinguished Associate Award, American College of Cardiology
2014 Fellow, American College of Clinical Pharmacy
2013 Member, Academy of Research Excellence, University of Florida
2011 Drug Therapy Research Award – American Society of Health-System Pharmacists
2011 Best Paper Award – American College of Clinical Pharmacy, Cardiology Practice and Research Network
2011 Top Population Science Paper
Hypertension, Journal of the American Heart Association
2010 Fellow, American College of Cardiology
2009 Featured Poster Award
American Society of Hypertension, 24th Annual Scientific Meeting and Exposition, San Francisco, California
2009 ASHP Foundation Pharmacy Resident Practice-Based Research Grant Program Peer Review
2008 Clinical Science Award
The Consortium for Southeastern Hypertension Control (COSEHC), 15th Annual National Scientific Sessions, Baltimore, Maryland
2008 Vascular Biology / Blood Pressure Regulation
American Heart Association Peer Review, Committee R2
2007 Fellow, American Heart Association (FAHA.) and Council for High Blood Pressure Research.

2001	New Investigator Award American Heart Association, Council on Basic Cardiovascular Sciences, Seattle, Washington
1988	Roche Award for Outstanding Research Affecting Patient Care

COMMITTEE MEMBERSHIPS

2022-2023	Human Subjects Research Process Improvement Working Group
2021-2023	Faculty Search Committee, Artificial Intelligence, Clinical Decision Support
2020-2022	Member, Office of Clinical Research Advisory Committee – UF Health
2020-2021	Member, COVID-19 Clinical Research Reboot Task Force – UF Health
2020-2021	Member, COVID-19 Scientific Review Committee and Peer Assistance Working Group – UF Health
2020-2022	Member, Research Builds Working Group – UF Health
2018-2022	Education Workgroup Chair, CV Team Section, American College of Cardiology
2018-2022	Lifelong Learning Oversight Committee, American College of Cardiology
2018-2021	Publications and Editorial Coordination Committee, American College of Cardiology
2017-2018	TL1 CTSI Advisory Committee
2016-2018	UF Health Science Center Research Information Technology Committee
2015-2018	Cardiovascular Team Section Leadership Council, American College of Cardiology
2016-2017	FCCP Credentialing Committee, ACCP
2015-2016	Best Practices and Quality Improvement Committee, American College of Cardiology
2014-2016	Faculty Development Committee, Chairperson, College of Pharmacy, University of Florida
2013-2018	KL2 CTSI Advisory Committee, University of Florida
2012-2014	Team Based Care Committee, American College of Cardiology
2011-2014	Mentoring Committee, American College of Clinical Pharmacy, Cardiology Practice Research Network
2009-2018	Institutional Review Board, University of Florida
2007-2012	Nurse Education Committee, American College of Cardiology
2007-2013	APPCI Advisory Committee, University of Florida
1987-2004	Institutional Review Board, University of Florida
1989-1999	General Clinical Research Center Scientific Advisory Committee, University of Florida
1991-1995	Shands Hospital Biotechnology Committee (Subcommittee of Pharmacy and Therapeutics Committee)

TEACHING EXPERIENCE

Spring 2019-2021	GMS XXXX Cardiovascular Epidemiology - Hypertension
Summ 2019-2023	PHA 6613 Genetics of Complex Diseases – Kidney Diseases
Summ 2019-2023	PHA 6613 Genetics of Complex Diseases – Familial Hypercholesterolemia
Fall 2016-2022	PHA 5878C Patient Care 3 Course Module Leader: Hypertension
Sum 2015-2022	PHA5012, Clinical Applications of Personalized Medicine Bioethics and informed consent
Fall 2014-2015	PHA 5782, Pharmacotherapy II Dyslipidemia, Hypertension
Spring 2010-2021	GMS6413, Hypertension Research

	Clinical Trials in Hypertension, Diabetes and Metabolic Syndrome and Hypertension
Fall 2009-2013	PHA 5782, Pharmacotherapy II Dyslipidemia, Stable Ischemic Heart Disease, Hypertension
Spring 2010-2014	PHA 6935, Practice and Procedures of the IRB
Fall 2008-2012	GMS 7039, Intro to Clinical Translational Research Panel participant: "How I Got Funded"
Fall 2006, 2007	GMS 6181, Intro to Clinical Translational Research "Out into the Community and Back to the Bench"
2006-2021	PHA 56**, Clinical Pharmacogenomics "Ethical Conduct of Human Subjects Research"
2000-2003	Department of Medicine Resident Rotation Preceptor Cardiovascular Research
1995-1999	Basic and Clinical Research Course for Physicians and Fellows
1987-1999	Contemporary Pharmacy Systems for Pharm.D. Students University of Florida, College of Pharmacy

RESEARCH SUPPORT AND PROJECTS

Extramural Funding

2U01HG007269-05 (Johnson PI) 09/2018-06/2025
NHGRI
Sparking Advancements in Genomic Medicine
This project's goal is to be a clinical group in the IGNITE-2 network, to participate in the activities of the IGNITE-2 network and execute clinical trials of genomic medicine implementation across our clinical sites.
Role: Co-I

2U01 HG007269-05 REVISED (Johnson PI) 09/2018-06/2025
NHGRI
Sparking Advancements in Genomic Medicine
This project's goal is to be a clinical group in the IGNITE-2 network, to participate in the activities of the IGNITE-2 network and execute clinical trials of genomic medicine implementation across our clinical sites.
Role: Regulatory Lead, UF Adult CV & Metabolic Risk

Completed Research (2007-Present)

PCORI PaCR (Cooper-DeHoff, Pletcher M-PI) 09/2018-06/2023
Using PCORnet to Compare Blood Pressure Control Strategies
This project's goal is to establish a virtual BP Control Laboratory and implement various tools and techniques to improve blood pressure control.
Role: MPI

PR161603 (Pepine PI) 09/2017-09/2022
Department of Defense CDMRP
Ischemia-Intensive Medical Treatment Reduces Events in Women with Nonobstructive CAD
This project's goal is to determine if medications to modify risk factors in women with angina and coronary arteries without severe obstruction will reduce adverse outcomes.
Role: Co-I

6292-2020-R2TC-B17 Yale Center for Outcomes Research and Evaluation (Cooper-DeHoff Local PI)
Uncontrolled Hypertension
This project established computable phenotypes for controlled and uncontrolled hyperetension that can be used to estimate #s of eligible subjects within a healthcare system that could participate in hypertension research.

Creating the Healthiest Generation UF Moonshot Initiative (Rassumsen, Cooper-DeHoff, Parker MPI) 01/2019-12/2021
Reengineering the Clinical Environment for Precision Medicine
This project's goals are to develop: 1) approaches and clinical tools for incorporating genomic and other biomarker data, personal lifestyle and community information into clinical decision-making and 2) evidence for justifying incorporation of these approaches as part of usual care, and 3) to simultaneously build a rich data resource for future research.
Role: MPI

Patient-Centered Outcomes Research Institute (PCORI) (Cooper-DeHoff PI) 11/2018-10/2019
Cardiovascular Health Collaborative Research Group
This project's goal is to oversee and coordinate collaborative research across the PCORnet CDRNs in the area of cardiovascular research.
Role: PI

UF CTSI Pilot Program (Cooper-DeHoff M PI) 11/01/2015-10/03/2018
Optimizing Precision of HTN Care to Maximize BP Control Pilot (OPTI-BP Pilot)

NIH/NIGMS U01 GM074492 (Cooper-DeHoff and Johnson) 08/1/2010-07/31/2017
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

South East Center for Integrative Metabolomics (Cooper-DeHoff PI) 06/2014-10/2016
Pilot and Feasibility Project Award
This was a targeted pharmacometabolomic investigation of the acylcarnitine pathway and incident impaired fasting glucose.

MMC15-01, Health Equity Research Institute (Cooper-DeHoff PI) 05/01/2015-04/30/2016
Optimizing Rural Health Clinic Infrastructure to Maximize BP Control (OPTI-BP)
This grant explored the causes of health disparities with regard to blood pressure control in the rural health clinic community.

UF CTSI Pilot Award (Cooper-DeHoff PI) 01/2014
The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics

NIH/NHLBI K23 HL086558 (Cooper-DeHoff PI) 02/01/2007-01/31/2012
Metabolic Effects of Antihypertensive Drugs
This project's goal was to overcome gaps in knowledge regarding the metabolic impact of antihypertensive drugs in patients with metabolic syndrome and will provide data to influence future prescribing patterns.

NIH/NIGMS U01GM074492 (Johnson PI) 08/03/2005-07/31/2010
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR).

This project's goal was to obtain high quality phenotype data, including both home and ambulatory measures of blood pressure (BP) response, and lipid and insulin sensitivity measures of adverse metabolic responses will be related to genetic variation.
Role: Co-I

NIH/NHLBI (Cooper-DeHoff PI) 05/2008
Understanding the Relationship of Transcription Factor 7-like Gene (***TCF7L2)***
Polymorphisms and Incidence of Diabetes in an Ethnically Diverse Hypertensive Heart Disease Population.

UF CTSI (Cooper-DeHoff PI) 10/2008-10/2009
PPARγ Expression in Key Metabolic Organ Systems is Modulated by Treatment with Thiazide Diuretics and ACE Inhibition.

Pfizer Pharmaceuticals (Pepine PI) 08/2001-02/2008
Effect of Sildenafil on Coronary and Systemic Vascular Function in Women with Chest Pain.
Role:Co-I

University of Florida (Cooper-DeHoff PI) 02/2004-02/2007
WISE / Women Take Heart Collaboration.

Cleveland Clinic and Pfizer (Pepine PI) 02/06/2007-12/29/2007
***Prospective Randomized Evaluation of Celecoxib Integrated Safety, vs. Ibuprofen or Naproxen-PRECISION*.**
Role: Co-I

NIH/NHLBI R01HL074730 (Johnson PI) 09/26/2003-08/31/2007
Hypertension Pharmacogenetics.
This project tested the following hypotheses: Hypothesis 1: Genetic variability in the proteins important to verapamil's pharmacologic action contribute to interpatient variability in verapamil's antihypertensive effect; Hypothesis 2: Antihypertensives that target the underlying molecular/genetic basis of a patient's HTN will result in better outcomes than antihypertensives that do not target the underlying pathophysiology; Hypothesis 3: Use of molecular markers to define genetic heterogeneity in the study population is superior to race/ethnicity information in genetic associations with drug response
Role: Co-I

PROFESSIONAL OFFICES AND APPOINTMENTS

2018-2022 Chair, American College of Cardiology, CV Team Education Work Group

2014-Present Faculty Advisor, Phi Delta Chi Pharmacy Fraternity, Delta Delta Chapter

1987-1989 Secretary, North Central Florida Society of Hospital Pharmacists

1986-1987 Western Regional Alumni Director, Phi Delta Chi Pharmaceutical Fraternity

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

American College of Clinical Pharmacy
American Heart Association
American College of Cardiology
American Society of Health System Pharmacists

Florida Society of Health-System Pharmacists
North Central Florida Society of Health System Pharmacists
Phi Delta Chi Pharmacy Fraternity

PUBLICATIONS

Articles in Refereed Journals:

1. **Cooper RM**. Potassium Iodide for Radiation Exposure. *Drug Intelligence and Clinical Pharmacy*. 1988;22:33-34. DOI: 10.1177/106002808802200107.
2. Huang D, Harman E, Friedman B, Tanaka W, **Cooper RM**, Hendeles L. Effect of a leukotriene synthesis inhibitor (MK-886) on the early and late asthmatic response. *Chest* 1990;98:50S. DOI:10.1378/chest.98.2_Supplement.36S.
3. Hendeles L, Davison D, Blake K, Harman E, **Cooper RM**, Margolskee D. Leukotriene D_4 is an important mediator of antigen-induced bronchoconstriction: Attenuation of dual response with MK-571, a specific LTD_4 receptor antagonist. *J Allergy Clin Immunol* 1990;85(1):197.
4. Murgatroyd RJ, **Cooper RM**. Readability of informed consent forms. *Am J of Hosp Pharm*. 1991;48(12):2651-2652. PMID: 1814213.
5. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, **Cooper-DeHoff RM**, Volkers P, Zelles P. Rationale and design of the INternational VErapamil SR/Trandolapril STudy (INVEST): An internet-based randomized trial in coronary artery disease patients with hypertension. *J Am Coll Cardiol*. 1998;32(5):1228-1237. PMID: 9809930.
6. Grant MB, Mames RN, Fitzgerald C, Hazariwala KG, **Cooper-DeHoff R**, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. *Diabetes Care*. 2000;23(4):504-509. PMID: 10857943.
7. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, **Cooper-DeHoff R**, Caballero S, Estes KS. Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy: A Randomized Controlled Study: Response to Gehrs. *Diabetes Care*. 2001;24(1):182-183. DOI: 10.2337/diacare.24.1.182-a.
8. **Cooper-DeHoff RM**, Handberg E, Heissenberg, C, Johnson, K. Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial. *Clin Cardiol*. 2001;24(S5):V14-V16. PMID: 11712771.
9. Conti CR, **Cooper-DeHoff RM**. How will INVEST and other hypertension trials change clinical practice? *Clin Cardiol*. 2001;24(S5):V24-V29. PMID: 11712773.
10. Pepine CJ, **Cooper-DeHoff RM,** Weiss RJ, Koren M, Bittar N, Thadani U, Minkwitz MC, Michelson EL, and Hutchinson HG. Comparative Efficacy and safety of nisoldipine and amlodipine (CESNA-II) study investigators. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. *Am J Cardiol*. 2003;91(3):274-279. PMID: 12565082.
11. Pepine CJ, Handberg EM, **Cooper-DeHoff RM**, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The INternational VErapamil-Trandolapril STudy (INVEST): a randomized controlled trial *JAMA*. 2003;290(21):2805-2816. PMID: 14657064.
12. Pepine CJ, **Cooper-DeHoff RM**. Cardiovascular therapies and risk for development of diabetes. *J Am Coll Cardiol*. 2004;44(3):509-512. PMID: 15358012.
13. **Cooper-DeHoff RM**, Handberg EM, Cohen J, Kowey P, Messerli FH, Mancia G, Cangiano JL, Gaxiola E, Garcia-Barreto D, Hewkin AC, Pepine CJ; INVEST Investigators. Characteristics of contemporary patients with hypertension and coronary artery disease. *Clin Cardiol*. 2004;27(10):571-576. PMID: 15553310.

14. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, **Cooper-DeHoff RM**, Pepine CJ; INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-trandolapril STudy. *Hypertension*. 2004;44(5):637-642. PMID: 15381674.
15. Zineh I, **Cooper-DeHoff RM**, Wessel TR, Arant CB, Sleight P, Geiser EA, Pepine CJ. Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-trandolapril STudy (INVEST). *Clin Cardiol*. 2005;28(7):321-328. PMID: 16075824.
16. Elliott WJ, Hewkin AC, Kupfer S, **Cooper-DeHoff RM**, Pepine CJ. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. *J Clin Hypertension*. 2005;7(11):654-663. PMID: 16278523.
17. **Cooper-DeHoff RM,** Pepine CJ. Editorial: Ranolazine is associated with cardiovascular and metabolic improvement: A win-win for patients with diabetes. *Eur Heart J*. 2006;27(1):5-6. PMID: 16267073.
18. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, **Cooper-DeHoff RM**, Handberg EM, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L. Predictors of adverse outcomes among patients with hypertension and coronary artery disease. *J Am Coll Cardiol*. 2006;47(3):547-551. PMID: 16458134.
19. **Cooper-DeHoff RM**, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ. Blood pressure control and cardiovascular outcomes in high risk Hispanic patients – Findings from the International Verapamil SR/Trandolapril Study (INVEST). *Am Heart J*. 2006;151(5):1072-1079. PMID: 16644338.
20. **Cooper-DeHoff RM**, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ. Predictors of Development of Diabetes Mellitus in Patients with Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). *Am J Cardiol*. 2006;98(7):890-894. PMID: 16996868.
21. Epstein BJ and **Cooper-DeHoff RM.** Effect of Ramipril on the Incidence of Diabetes – Letter to the Editor. *N Engl J Med*. 2007;356(5):523. PMID: 17269176.
22. Bakris GL, **Cooper-DeHoff RM**, Zhou Q, Kupfer S, Champion A, Pepine CJ, for the INVEST Investigators. Dual Therapy in Hypertensive Patients with Coronary Artery Disease: The Role of Calcium Channel Blockers and B-Blockers. *Am. J. Cardiovasc. Drugs*. 2007;7(Suppl.1):25-29. PMID: 19845074.
23. Langaee TY, Gong Y, Yarandi HN, Katz DA, **Cooper-DeHoff RM,** Pepine CJ, Johnson JA. Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil. *Clinical Pharmacology & Therapeutics*. 2007;81(3):386-391. PMID: 17339868.
24. **Cooper-DeHoff RM**, Zhou Q, Gaxiola E, Cangiano JL, Garcia-Barreto D, Handberg E, Pepine CJ. Influence of Hispanic Ethnicity on Blood Pressure Control and Cardiovascular Outcomes in Women with CAD and Hypertension: Findings from INVEST. *Journal of Women's Health*. 2007;16(5):632-640. PMID: 17627399.
25. Brunner M, **Cooper-DeHoff RM**, Gong Y, Karnes JH, Langaee TY, Pepine CJ, Johnson JA. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/ Trandolapril [INVEST] Study). *Am J Cardiol*. 2007;99(11):1549-1554. PMID: 17531579. PMCID: PMC2720593.
26. Beitelshees AL, Gong Y, Wang D, Schork NJ, **Cooper-DeHoff RM**, Langaee TY, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA; INVEST Investigators. *KCNMB1* genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). *Pharmacogenetics and Genomics*. 2007;17(9):719-729. PMID: 17700361. PMCID: PMC2713584.
27. Uretsky S, Messerli FH, Bangalore S, Champion A, **Cooper-DeHoff RM**, Zhou Q, Pepine CJ. Obesity Paradox in Patients with Hypertension and Coronary Artery Disease. *The American Journal of Medicine*. 2007;120(10): 863-870. PMID: 17904457.

28. **Cooper-DeHoff RM**, Pepine CJ. Metabolic Syndrome and Cardiovascular Disease: Challenges and Opportunities. *Clinical Cardiol* 2007;30(12): 593-597. PMID: 17607758. PMCID: PMC2794411.
29. Coca A, Messerli FH, Benetos A, Zhou Q, Champion A, **Cooper-DeHoff RM**, Pepine CJ. Predicting Stroke Risk in Hypertensive Patients with Coronary Artery Disease: A Report from the INVEST. *Stroke*. 2008;39(2):343-348. PMID: 18162623. PMCID: PMC2805179.
30. Pepine CJ, **Cooper-DeHoff R**, Coca A, Messerli F, Bénétos A. Response to Letter by Barrios and Escobar. *Stroke.* 2009;40(6):e470. DOI: 10.1161/STROKEAHA.108.521575.
31. Kolloch R, Legler UF, Champion A, **Cooper-DeHoff RM**, Handberg E, Zhou Q, and Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST) *Eur Heart J*. 2008;29(10):1327-1334. PMID: 18375982. PMCID: PMC2805436.
32. Pacanowski MA, Zineh I, Li H, Johnson BD, **Cooper-DeHoff RM**, Bittner V, McNamara DM, Sharaf BL, Bairey Merz CN, Pepine CJ, Johnson JA. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. *J Transl Med*. 2008;6:11. PMID: 18331634. PMCID: PMC2329599.
33. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, **Cooper-DeHoff RM**, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health--National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. *J Clin Endocrinol Metab*. 2008;93(4):1276-1284. PMID: 18182456. PMCID: PMC2291491. (Retracted).
34. Gerhard T, Gong Y, Beitelshees AL, Mao X, Lobmeyer MT, **Cooper-DeHoff RM**, Langaee TY, Schork NJ, Shriver MD, Pepine CJ, Johnson JA; INVEST Investigators. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). *Am Heart J*. 2008;156(2):397-404. PMID: 18657677. PMCID: PMC2547143.
35. Pacanowski MA, Gong Y, **Cooper-DeHoff RM**, Schork N, Shriver M, Langaee T, Pepine CJ, Johnson J. Beta-Adrenergic Receptor Gene Polymorphisms and beta-Blocker Treatment Outcomes in Hypertension. *Clin Pharmacol Ther*. 2008;84(6):715-721. PMID: 18615004. PMCID: PMC2675574.
36. **Cooper-DeHoff RM.** Thiazide Induced Dysglycemia – It's Time To Take Notice. *Exp Rev of Card Ther*. 2008;6(10):1291-1294. PMID: 19018679. PMCID: PMC3891644.
37. Johnson AD, Gong Y, Wang D, Langaee TY, Shin J, **Cooper-DeHoff RM**, Schork NJ, Binkley P, Pepine CJ, Johnson JA, Sadee W. Promoter polymorphisms in ACE (angiotensin-I converting enzyme) associated with clinical outcomes in hypertension. *Clin Pharmacol Ther*. 2009;85(1):36-44. PMID: 18946466. PMCID: PMC2709290.
38. **Cooper-DeHoff RM**, Pacanowski MA, Pepine, CJ. Cardiovascular Therapies and Associated Glucose Homeostasis: Implications across the Dysglycemia Continuum. *J Am Coll Cardiol*. 2009;53(5 Suppl):S28-34. PMID: 19179214. PMCID: PMC2655143.
39. Denardo SJ, Messerlli FH, Gaxiola E, Aranda JM, **Cooper-DeHoff RM**, Handberg EM, Gong Y, Champion A, Zhou Q, Pepine, CJ. Characteristics and Outcomes of Revascularized Patients with Hypertension – An International Verapamil SR-Trandolapril Substudy. *Hypertensio*n.2009; 53(4):624-630. PMID: 19237684. PMCID: PMC2794408.
40. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, **Cooper-DeHoff RM**, Gums J, Curry RW, Gong Y, Beitelshees AL, Schwartz G, Turner ST. Pharmacogenomics of Antihypertensive Drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Am Heart J*. 2009;157(3):442-449. PMID: 19249413. PMCID: PMC2671287.

41. Pacanowski MA, Zineh I, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Genetic and Pharmacogenetic Associations Between *NOS3* Polymorphisms, Blood Pressure, and Cardiovascular Events in Hypertension. *Am J Hypertens*. 2009;22(7):748-753. PMID: 19407804. PMCID: PMC2803093.
42. Gulati M, **Cooper-DeHoff RM**, McClure C, Johnson BD, Shaw LJ, Handberg EM, Zineh I, Kelsey SF; Arnsdorf MF, Black HR, Pepine CJ, Bairey Merz CN. Adverse Cardiovascular Outcomes In Women with Nonobstructive Coronary Artery Disease: A Report From The National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study and The St James Women Take Heart (WTH) Project. *Arch Int Med*. 2009;169(9):843-850. PMID: 19433695. PMCID: PMC2782882.
43. Gong Y, Handberg EM, Gerhard T, **Cooper-DeHoff RM**, Ried D, Johnson JA, Pepine CJ. Systolic Blood Pressure and Subjective Well-Being in Patients with Coronary Artery Disease. *Clinical Cardiology*. 2009;32(11):627-632. PMID: 19711440. PMCID: PMC2810952.
44. Karnes JH, **Cooper-DeHoff RM**. Antihypertensive Medications: Benefits of BP Lowering and Hazards of Metabolic Effects. *Exp Rev of Card Ther* 2009;7(6):689-702. PMID: 19505284. PMCID: PMC2799117.
45. Beitelshees AL, Navara H, Wang D, Gong Y, Wessel J, Moss J, Langaee TY, **Cooper-DeHoff RM**, Sadee W, Pepine CJ, Schork NJ, Johnson JA. *CACNA1C* gene Polymorphisms, Cardiovascular Disease Outcomes and Treatment Response. *Circ Genetics*. 2009;2(4):362-370. PMID: 20031608. PMCID: PMC2761685.
46. Johnson JA, Gong Y, Bailey KR, **Cooper-DeHoff RM**, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshees AL, Boerwinkle E, Gums JG. Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order. *Clin Pharmacol Ther*. 2009;86(5):533-539. PMID: 19571804. PMCID: PMC2765524.
47. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, **Cooper-DeHoff RM**, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Pharmacotherapy*, 2009;29(10):1157-1165. PMID: 19792989. PMCID: PMC2777624.
48. **Cooper-DeHoff RM**, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ. INVEST revisited: Review of Findings from the International Verapamil SR Trandolapril Study. *Expert Rev Cardiovasc Ther*. 2009;7(11):1329-1340. PMID: 19900016. PMCID: PMC2800790.
49. **Cooper-DeHoff RM,** Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated with Antihypertensive Medications. *Hypertension.* 2010;55(1):61-68. PMID: 19917874. PMCID: PMC2811061.
50. Bavry AA, Anderson RD, Gong Y, Denardo SJ, **Cooper-DeHoff RM**, Handberg EM, Pepine CJ. Outcomes Among Hypertensive Patients with Concomitant Peripheral and Coronary Artery Disease: Findings from the International Verapamil-SR/Trandolapril Study. *Hypertension*. 2010;55(1):48-53. PMID: 19996066. PMCID: PMC3000120.
51. **Cooper-DeHoff RM**. Drug Induced Diabetes – Understanding Which CV Drugs are Involved and Who Is At Highest Risk [transcript]. Cardiosource Web Site, American College of Cardiology Foundation. Available at http://www.cardiosource.com/expertopinions/hottopics/articleasp?paperID=380. Accessed February 9, 2010.
52. **Cooper-DeHoff RM**, Pepine CJ. The Use of Diuretics Plus Calcium Channel Blockers for Hypertension May Be Associated with a Higher risk of Myocardial Infarction but not Stroke Compared with the Combination of Diuretics plus Beta Blockers. *Evid Based Med* 2010;15(3):92-93. PMID: 20522694. PMCID: PMC2997535.

53. Bairey Merz CN, Olson BM, McClure C, Yang Y, Symons J, Sopko G, Kelsey SF, Handberg EM, Johnson BD, **Cooper-DeHoff RM**, Sharaf B, Rogers WJ, Pepine CJ. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2010;159(6):987.e1-987.e7. PMID: 20569710. PMCID: PMC2918903.
54. Duarte JD, **Cooper-DeHoff RM**. Mechanisms for Blood Pressure-Lowering and metabolic Effects of Thiazide and Thiazide-Like Diuretics. *Expert Rev Cardiovasc Ther*. 2010;8(6):793-802. PMID: 20528637. PMCID: PMC2904515.
55. **Cooper-DeHoff RM**, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients with Diabetes and Coronary Artery Disease. *JAMA*. 2010;304(1):61-68. PMID: 20606150. PMCID: PMC3008411.
56. **Cooper-DeHoff RM**, Gong Y, Pepine CJ. Hypertension Control and Cardiovascular Outcomes Among Patients with Diabetes and Coronary Artery Disease—Reply. *JAMA*. 2010;304(15):1672-1673. DOI:10.1001/jama.2010.1465.
57. Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, **Cooper-DeHoff RM**, Handberg EM, Champion A, Pepine CJ. Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An International Verapamil SR-Trandolparil Study (INVEST) Substudy. *Am J Med*. 2010;123(8):719-726. PMID: 20670726. PMCID: PMC3008373.
58. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, **Cooper-DeHoff RM**, Handberg EM, Gong Y, Champion A, Zhou Q and Pepine CJ. Coronary Revascularization Strategy and Outcomes According to Blood Pressure (from the International Verapamil SR-Trandolparil Study (INVEST). *Am J Cardiol* 2010;106(4):498-503. PMID: 20691307. PMCID: PMC3005196.
59. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, **Cooper-DeHoff RM**, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. *Am J Hypertens.* 2010;23(9):1014-1022. PMID: 20725057. PMCID: PMC2941699.
60. Navare HH, Frye RF, **Cooper-DeHoff RM**, Shuster JJ, Hall K, Schmidt SOF, Turner ST, Johnson JA. Atenolol Exposure and Risk for Development of Adverse Metabolic Effects: A Pilot Study. *Pharmacotherapy*. 2010;30(9):872-878. PMID: 20795842. PMCID: PMC2999810.
61. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, Moss JI, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Genetic variation in the beta 2 subunit of the voltage-gated calcum chanel and pharmacogenetic association with adverse cardiovascular outcomes in the International Verapamil SR-Trandolparil Study GENEtic Substudy (INVEST-GENES). *Circ Cardiovasc Genet*. 2010;3(6):548-555. PMID: 21156931. PMCID: PMC3060561.
62. Beitelshees AL, Johnson JA, Hames ML, Gong Y, **Cooper-DeHoff RM**, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. *PLoS One*. 2010;5(12):e15180 PMID: 21170323. PMCID: PMC3000815.
63. Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, **Cooper-DeHoff RM**, Beitelshees AL, Bailey KR, Boerwinkle EA, Pepine CJ, Johnson JA. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. *Pharmacogenet Genomics*. 2011;21(1):42-49. PMID: 21127457. PMCID: PMC3028503.

64. **Cooper-DeHoff RM**, Egelund EF, Pepine CJ. Blood Pressure Lowering in Patients with Diabetes – One Level may Not Fit All. *Nature Review Cardiol* 2011;8(1):42-49. PMID: 21079637. PMCID: PMC3016088.
65. Gong Y, Beitelshees AL, **Cooper-DeHoff RM**, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients with Coronary Artery Disease. *Circ Cardiovasc Genet*. 2011;4(2):169-178. PMID: 21372283. PMCID: PMC3101633.
66. Gong Y, Beitelshees AL, **Cooper-DeHoff RM**, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Response to Letter Regarding Article "Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease". *Circ Cardiovasc Genet*. 2011;4(4):e12. DOI: 10.1161/CIRCGENETICS.111.960807.
67. Price ET, Pacanowski MA, Martin MA, **Cooper-DeHoff RM**, Pepine CJ, Zineh I, Johnson JA. Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. *Pharmacogenetics and Genomics* 2011;21(6):333-340. PMID: 21562465. PMCID: PMC3093636.
68. Bavry AA, Khaliq A, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. *Am J Med*. 2011;124(7):614-620. PMID: 21596367. PMCID: PMC4664475.
69. Denardo SJ, Wen X, Handberg EM, Bairey Merz CN, Sopko GS, **Cooper-DeHoff RM**, Pepine CJ. Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study. *Clin Cardiol*. 2011;34(8):483-487. PMID: 21780138. PMCID: PMC3151010.
70. Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, **Cooper-DeHoff RM**, Sopko G, Sharaf BM, Kelsey SF, Merz CN, Pepine CJ. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and macrovascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2011;162(4):678-684. PMID: 21982660. PMCID: PMC3191889.
71. Davoodi-Semiromi A, **Cooper-DeHoff RM**. Correspondence regarding "Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats". *Biochem Pharmacol*. 2012;83(6):821. PMID: 22227275.
72. Smith SM, Gong Y, Turner ST, **Cooper-DeHoff RM**, Beitelshees AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. *Am J Hypertens*. 2012;25(3):359-365. PMID: 22089105. PMCID: PMC3288583.
73. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, **Cooper-DeHoff RM**, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, Gong Y, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langaee TY, Lawlor DA, Li M, Lobmeyer MT, Maitland-van der Zee AH, Meijs MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolffenbuttel BH, Young T, Zafarmand MH, Zmuda JM; Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Sever P, Poulter N, Caulfield M,

Dominiczak A, Shields DC, Bhatt DL, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW 2nd, Farrall M, FitzGerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs FW, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *Am J Hum Genet*. 2012;90(3):410-425. PMID: 22325160. PMCID: PMC3309185.

74. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, **Cooper-DeHoff, RM**, Boerwinkle E, Johnson JA, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. *J Transl Med*. 2012;10:47. PMID: 22413836. PMCID: PMC3342146.
75. Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, **Cooper-DeHoff RM**, Beiltelshees AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. *J Transl Med*. 2012;10:56. PMID: 22440088. PMCID: PMC3320544.
76. Davoodi-Semiromi A, Wasserfall CH, Xia CQ, **Cooper-DeHoff RM**, Wabitsch M, Clare-Salzler M, Atkinson M. The Tyrphostin agent AG-490 Prevents and Reverses Type 1 Diabetes in NOD Mice. *PLoS One*. 2012;7(5):e36079. PMID: 22615750. PMCID: PMC3351395.
77. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, **Cooper-DeHoff RM**, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for *SLCO1B1* and simvastatin-induced myopathy. *Clin Pharmacol Ther*. 2012;92(1):112-117. PMID: 22617227. PMCID: PMC3384438.
78. Gerhard T, Delaney JA, **Cooper-DeHoff RM**, Shuster J, Brumback BA, Johnson JA, Pepine CJ, Winterstein AG. Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. *BMC Med Res Methodol*. 2012;12:119. PMID: 22866767. PMCID: PMC3573973.
79. Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshees AL, Turner ST, Chapman AB, **Cooper-DeHoff RM**, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 (GRK4) polymorphisms: Beta-blocker pharmacogenetics and treatment related outcomes in hypertension. *Hypertension.* 2012;60(4):957-964. PMID: 22949529. PMCID: PMC3462355.
80. Gong Y, McDonough CW, Wang Z, Hou W, **Cooper-DeHoff RM**, Langaee TY, Beitelshees AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives: Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Circ Cardiovasc Genet*. 2012;5(6):686-691. PMID: 23087401. PMCID: PMC3529147.
81. Asselbergs FW, Guo Y, van Iperen EPA, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera Castillo B, Appelman YE, Barnard J, Baumert J, Beitelshees AL, Bhangale TR, Ida Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, Liu K, McDonough CW, Meijs MFL, Middelberg RPS, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SPR, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JMA, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, **Cooper-DeHoff RM**, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet*. 2012;91(5):823-838. PMID: 23063622. PMCID: PMC3487124.

82. Guo Y, Lanktree MB, Taylor KC, Hakonsarson H, Lange LA, Keating BJ; **Cooper-DeHoff RM**, et al. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. *Hum Mol Genet*. 2012, 22(1):184-201. PMID: 23001569. PMCID: PMC3522401.
83. Davoodi-Semiromi A, Wasserfall CH, Hassanzadeh A, **Cooper-DeHoff RM**, Wabitsch M, Atkinson M. Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes. *Immunogenetics*. 2013;65(1):83-90. PMID: 23081744. PMCID: PMC4538928.
84. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, Langaee TY, Beitelshees AL, **Cooper-DeHoff RM**, Boerwinkle E, Johnson JA. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential *YEATS4* expression. *Pharmacogenomics J*. 2013;13(3):257-263. PMID: 22350108. PMCID: PMC3360116.
85. Karnes JH, Langaee TY, McDonough CW, Chang SW, Ramos M, Catlin JR Jr, Casanova OE, Gong Y, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. Lack of association of the *HMGA1* IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. *J Transl Med*. 2013;11:12. PMID: 23302499. PMCID: PMC3558451.
86. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JM, Gieger C, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Most PJ, Van Iperen EP, van Setten J, Vonk JM, Zhang L, Beitelshees AL, Berenson GS, Bhatt DL, Boer JM, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, **Cooper-DeHoff RM**, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array. *Hum Mol Genet*. 2013;22(8):1663-1678. PMID: 23303523. PMCID: PMC3657476.
87. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshees AL, Boerwinkle E, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. Association of variants in *NEDD4L* with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens*. 2013;31(4):698-704. PMID: 23353631. PMCID: PMC3756535.
88. **Cooper-DeHoff RM**, Chang SW, Pepine CJ. Calcium antagonists in the treatment of coronary artery disease. *Curr Opin Pharmacol*. 2013;13(2):301-308. PMID: 23402734.
89. Calhoun M, Cross LB, **Cooper-DeHoff RM**. Clinical utility of β-blockers for primary and secondary prevention of coronary artery disease. *Expert Rev Cardiovasc Ther*. 2013;11(3):289-291. PMID: 23469908.
90. Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, **Cooper-DeHoff RM**, Beitelshees AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R; Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. *PLoS One*. 2013;8(3):e57639. PMID: 23536766. PMCID: PMC3594230.
91. McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O, Pepine CJ, Dominiczak AF, **Cooper-DeHoff RM**, Johnson JA. Pharmacogenomic association of non-synonymous SNPs in *SIGLEC12*, *A1BG*, and the Selectin Region and Cardiovascular Outcomes. *Hypertension*. 2013;62(1):48-54. PMID: 23690342. PMCID: PMC3686553.
92. **Cooper-DeHoff RM**, Bird ST, Nichols GA, Delaney JA, Winterstein AG. Antihypertensive Drug Class Interactions and risk for Incident Diabetes: a Nested Case Control Study. *Journal of the American Heart Association*. 2013;2(3):e000125. PMID: 23752710 PMCID: PMC3698771.
93. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L,

Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstrand B, Manunta P, Kontula K, Dominiczak AF, **Cooper-DeHoff RM**, Johnson JA. Genomic association analysis of common variants influencing antihypertensive responses to hydrochlorothiazide. *Hypertension.* 2013;62(2):391-397. PMID: 23753411. PMCID: PMC3780966.

94. **Cooper-DeHoff RM,** Elliott WJ. Generic Drugs for Hypertension: Are They Really Equivalent? *Curr Hypertens Rep*. 2013;15(4):340-345. PMID: 23700299. PMCID: PMC3715996.
95. **Cooper-DeHoff RM.** The Next 10 years in antihypertensive treatment. *Expert Rev Cardiovasc Ther.* 2013;11(6)669-671. PMID: 23750675.
96. Winchester DE, **Cooper-DeHoff RM**, Gong Y, Handberg EM, Pepine CJ. Mortality Implications of Angina and Blood Pressure in Hypertensive Patients with Coronary Artery Disease: New Data from Extended Follow-Up of the International Verapamil/Trandolapril Study (INVEST). *Clin Cardiol*. 2013;36(8):442-447. PMID: 23720247. PMCID: PMC3775918.
97. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MHA, Buford TW, El Rouby NM, Sá ACC, Langaee TY, Gums JG, Chapman AB, **Cooper-DeHoff RM**, Turner ST, Gong Y, Johnson JA. Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *PLoS One*. 2013;8(10):e76984. PMID: 24116192. PMCID: PMC3792156.
98. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langaee TY, Pepine CJ, Johnson JA, and **Cooper-DeHoff RM**. Impact of *TCF7L2* single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. *Pharmacogenet Genomics*. 2013;23(12):697-705. PMID: 24128935. PMCID: PMC3893755.
99. Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Del-Aguila J, Boerwinkle EA, Pepine CJ, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Association of *KCNJ1* variation with change in fasting glucose and new onset diabetes during HCTZ treatment. *Pharmacogenomics J*. 2013;13(5):430-436. PMID: 22907731. PMCID: PMC3529742.
100. Bavry AA, Kumbhani DJ, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Simple integer risk score to determine prognosis of patients with hypertension and chronic stable coronary artery disease. *J Am Heart Assoc*. 2013;2(4):e000205. PMID: 23948642. PMCID: PMC3828777.
101. Del-Aguila JL, Beitelshees AL, **Cooper-DeHoff RM**, Chapman AB, Gums JG, Bailey K, Gong Y, Turner ST, Johnson JA, Boerwinkle E. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. *Pharmacogenomics J*. 2014;14(1):35-40. PMID: 23400010. PMCID: PMC3812324.
102. Chapman AB, Cotsonis G, Parekh V, Schwartz GL, Gong Y, Bailey KR, Turner ST, Gums JG, Beitelshees AL, **Cooper-DeHoff RM**, Boerwinkle E, Johnson JA. Night Blood Pressure Responses to Atenolol and Hydrochlorothiazide in Black and White Patients with Essential Hypertension. *Am J Hypertens*. 2014;27(4):546-554. PMID: 23886594. PMCID: PMC3958600.
103. Gong Y, McDonough CW, Beitelshees AL, O'Connell JR, Karnes JH, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA, **Cooper-DeHoff RM**. *PROX1* Gene Variant is Associated with Fasting Glucose Change after Antihypertensive Treatment. *Pharmacotherapy.* 2014;34(2):123-130. PMID: 24122840. PMCID: PMC3945213.
104. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, **Cooper-DeHoff RM**. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. *J Hypertens*. 2014;32(3):635-643. PMID: 24299915. PMCID: PMC4118668.
105. Smith SM, Pepine CJ, **Cooper-DeHoff RM**. Reply to 'Resistant hypertension revisited: definition and true prevalence'. *J Hypertens*. 2014;32(7):1547. PMID: 24984184.

106. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshees A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, **Cooper-DeHoff RM**, Gaunt TR, Gieger C, Gong Y, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, et al. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet*. 2014;23(9):2498-2510. PMID: 24345515. PMCID: PMC3988452.
107. Hlatky MA, Ray RM, Burwen DR, Margolis KL, Johnson KC, Kucharska-Newton A, Manson JE, Robinson JG, Safford MM, Allison M, Assimes TL, Bavry AA, Berger J, **Cooper-DeHoff RM**, Heckbert SR, Li W, Liu S, Martin LW, Perez MV, Tindle HA, Winkelmayer WC, Stefanick ML. Use of medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. *Circ Cardiovasc Qual Outcomes*. 2014; 7(1):157-62. PMID: 24399330. PMCID: PMC4548886.
108. Bavry AA, Handberg EM, Huo T, Lerman A, Quyyumi AA, Shufelt C, Sharaf B, Bairey Merz CN, **Cooper-DeHoff RM**, Sopko G, Pepine CJ. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2014;167(6):826-832. PMID: 24890531. PMCID: PMC4049218.
109. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith EN, Johnson T, Holmes MV, Padmanabhan S, Karczewski KJ, Almoguera B, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Gaunt TR, Gho JM, Gieger C, Goel A, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Melander O, Nelson CP, Nolte IM, Pankratz N, Price TS, Shaffer J, Shah S, Tomaszewski M, van der Most PJ, Van Iperen EP, Vonk JM, Witkowska K, Wong CO, Zhang L, Beitelshees AL, Berenson GS, Bhatt DL, Brown M, Burt A, **Cooper-DeHoff** RM, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood pressure related loci. *Am J Hum Genet*. 2014; 94(3):349-360. PMID: 24560520. PMCID: PMC3951943.
110. Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, Noel Bairey Merz C, Pepine CJ, **Cooper-DeHoff RM.** Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBI-Sponsored WISE Study. *J Am Heart Assoc*. 2014;3(1):e000660. PMID: 24584740 PMCID: PMC3959684.
111. **Cooper-DeHoff RM**, Hou W, Weng L, Baillie RA, Beitelshees AL, Gong Y, Shahin MH, Turner ST, Chapman A, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Is a Diabetes-Linked Amino Acid Signature Associated with Beta Blocker-Induced Impaired Fasting Glucose? *Circ Cardiovasc Genetics*. 2014; 7(2):199-205. PMID: 24627569. PMCID: PMC4050976.
112. Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, Staley BJ, Dong HJ, Allan RW, Liu JF, **Cooper-DeHoff RM**, Anderson RD, Conlon M, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical pharmacogenetics implementation: Approaches, successes, and challenges. *Am J Med Genetic C Semin Med Genet*. 2014;166C(1):56-67. PMID: 24616371. PMCID: PMC4076109.
113. Vandell AG, McDonough CW, Gong Y, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Hydrochlorothiazide-Induced Hyperuricaemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *J Intern Med.* 2014;276(5):486-497. PMID: 24612202. PMCID: PMC4130802.
114. Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Skaar TC, Chapman AB, Gums JG, Turner ST, Gong Y, **Cooper-DeHoff RM**, Johnson JA. Impact of *CYP2D6* polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. *Clin Pharmacol Ther*. 2014;96(2):175-181. doi: 10.1038/clpt.2014.62. PMID: 24637943. PMCID: PMC4111800.

115. Karnes JH, Gong Y, Arwood MJ, Gums JG, Hall KL, Limacher MC, Johnson JA, and **Cooper-DeHoff RM**. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. *Diabetes Res Clin Pract*. 2014;104(3):363-369. PMID: 24794890. PMCID: PMC4074403.
116. Voils SA, **Cooper-DeHoff RM**. Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10. *Diabetes & Metabolic Syndrome: Clinical Research and Reviews*. 2014;8(2):88-90. PMID: 24907172.
117. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshees AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, **Cooper-DeHoff RM**, Johnson JA. Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide. *Pharmacotherapy*. 2014;34(11):1132-1140. PMID: 25202885. PMCID: PMC4227953.
118. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, **Cooper-DeHoff RM**, Gong L, Klein TE, Wadelius M, Niemi M. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *SLC01B1* and simvastatin-induced myopathy: 2014 update. *Clin Pharmacol Ther*. 2014;96(4):423-428. PMID: 24918167. PMCID: PMC4169720.
119. Franceschini N, Chasman DI, **Cooper-DeHoff RM**, Arnett DK. Genetics, ancestry, and hypertension: implications for targeted antihypertensive therapies. *Curr Hypertens Rep*. 2014;16(8):461. PMID: 24903233. PMCID: PMC4886553.
120. Winterstein AG, Kubilis P, Bird S, **Cooper-DeHoff RM**, Nichols GA, Delaney JA. Misclassification in assessment of diabetogenic risk using electronic health records. *Pharmacoepidemiol Drug Saf.* 2014;23(8):875-881. PMID: 24923707. PMCID: PMC5012172.
121. Bangalore S, Gong Y, **Cooper-DeHoff RM**, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. *J Am Coll Cardiol*. 2014;64(8):784-793. PMID: 25145522. PMCID: PMC4193384.
122. Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, **Cooper-DeHoff RM**, Johnson JA. Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics. *Pharmacotherapy*. 2014;34(10):1102-1112. PMID: 25220280. PMCID: PMC4188772.
123. Fontana V*, McDonough CW*, Gong Y, El Rouby NM, Sá ACC, Taylor KD, Chen Y-D I, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. Large-Scale Gene-centric Analysis Identifies Polymorphisms for Resistant Hypertension. *J Am Heart Assoc*. 2014;3(6):e001398. *These authors contributed equally to this work. PMID: 25385345. PMCID: PMC4338734.
124. Bavry AA, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Impact of aspirin according to type of stable coronary artery disease: Insights from a large international cohort. *Am J Med*. 2015;128(2):137-143. PMID: 25447610.
125. Del-Aguila JL, **Cooper-DeHoff RM**, Chapman AB, Gums JG, Beitelshees AL, Bailey K, Turner ST, Johnson JA, Boerwinkle E. Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. *Pharmacogenomics J*. 2015;15(2):153-157. PMID: 25201287. PMCID: PMC4362777.
126. Weng L, Quinlivan E, Gong Y, Beitelshees AL, Shahin MH, Turner ST, Chapman AB, Gums JG, Johnson JA, Frye RF, Garrett TJ, **Cooper-DeHoff RM**. Association of Branched and Aromatic Amino Acids Levels with Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients. *Metab Syndr Relat Disord*. 2015;13(5):195-202. PMID: 25664967. PMCID: PMC4519105.
127. Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga D, Piras DA, Carpini SD, Velayutham D, Simonini M, Argiolas G, Pozzoli S, Troffa C, Glorioso V, Kontula KK, Hiltunen TP, Donner KM, Turner ST, Boerwinkle E, Chapman

AB, Padmanabhan S, Dominiczak AF, Melander O, Johnson JA, **Cooper-DeHoff RM**, Gong Y, Rivera NV, Condorelli G, Trimarco B, Manunta P, Cusi D, Glorioso N, Barlassina C. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. *J Hypertens*. 2015;33(6):1301-1309. PMID: 25695618. PMCID: PMC4484731.

128. Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, Gums JG, Gong Y, **Cooper-DeHoff RM**, Frau F, Glorioso V, Zaninello R, Salvi E, Glorioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula KK. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. *J Am Heart Assoc.* 2015;4(1):e001521. doi: 10.1161/JAHA.115.001778. PMID: 25622599. PMCID: PMC4330076.
129. Smith SM, **Cooper-DeHoff RM**. Home blood pressure monitoring with patient-intitiated drug titration reduces blood pressure in high-risk patients with hypertension. *Evid Based Med*. 2015;20(2):58. PMID: 25587130.
130. El Rouby N, **Cooper-DeHoff RM**. Genetics of Resistant Hypertension: A Novel Pharmacogenomics Phenotype. *Curr Hypertens Rep*. 2015;17(9):583. PMID: 26198781. PMCID: PMC4717470.
131. Gong Y, McDonough CW, Beitelshees AL, El Rouby N, Hiltunen TP, O'Connell JR, Padmanabhan S, Langaee TY, Schmidt SO, Curry RW, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Chapman AB, Turner ST, **Cooper-DeHoff RM**, Johnson JA. *PTPRD* Gene Associated with Blood Pressure Response to Atenolol and Resistant Hypertension. *J Hypertens*. 2015;33(11):2278-2285. PMID: 26425837. PMCID: PMC4788379.
132. Biel NM, Santostefano KE, DiVita BB, El Rouby N, Carrasquilla SD, Simmons C, Nakanishi M, **Cooper-DeHoff RM**, Johnson JA, Terada N. Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. *Stem Cells Transl Med*. 2015;4(12):1380-1390. PMID: 26494780. PMCID: PMC4675511.
133. Khaliq A, Johnson BD, Anderson RD, Bavry AA, **Cooper-DeHoff RM**, Handberg EM, Bairey Merz CN, Nicholls SJ, Nissen S, Pepine CJ. Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease: the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation Study. *Cardiovasc Endocrinol*. 2015;4(2):45-52. PMID: 26665010. PMCID: PMC4671302.
134. Rotroff D, Shahin M, Gurley S, Zhu H., Motsinger-Reif A, Meisner M, Beitelshees A, Fiehn O, Johnson J, El-Badawi M, Frye R, Gong Y, Weng L, **Cooper-DeHoff RM**, Kaddurah-Daouk R. Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. *CPT Pharmacometrics Syst Pharmacol*. 2015;4(11):669-679. PMID: 26783503. PMCID: PMC4716583.
135. Denardo SJ, Gong Y, **Cooper-DeHoff RM**, Farsang C, Keltai M, Szirmai L, Messerli FH, Bavry AA, Handberg EM, Mancia G, Pepine CJ. Effects of verapamil SR and atenolol on 24-Hour blood pressure and heart rate in hypertension patients with coronary artery disease: an International Verapamil SR-Trandolapril ambulatory monitoring substudy. *PLoS ONE*. 2015;10(4):e0122726. PMID: 25835002. PMCID: PMC4383326. Erratum in: Correction: Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy.
136. Denardo SJ, Gong Y, **Cooper-DeHoff RM**, Farsang C, Keltai M, Szirmai L, Messerli FH, Bavry AA, Handberg EM, Mancia G, Pepine CJ. Correction: Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. *PLoS ONE*. 2016;11(6):e0157212. PMID: 27258057. PMCID: PMC4892545. Erratum for: Effects of verapamil SR and atenolol on 24-Hour blood

pressure and heart rate in hypertension patients with coronary artery disease: an International Verapamil SR-Trandolapril ambulatory monitoring substudy.

137. Weng L, Taylor KD, Chen YD, Sopko G, Kelsey SF, Bairey Merz CN, Pepine CJ, Miller VM, Rotter JI, Gulati M, Goodarzi MO, **Cooper-DeHoff RM**. Genetic Loci Associated with Nonobstructive Coronary Artery Disease in Caucasian Women. *Physiol Genomics*. 2016;48(1):12-20. PMID: 26534935. PMCID: PMC4757024.
138. **Cooper-DeHoff RM**, Johnson JA. Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches. *Nat Rev Nephrol*. 2016;12(2):110-122. PMID: 26592190. PMCID: PMC4778736.
139. Gong Y, Wang Z, Beitelshees AL, McDonough CW, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Pharmacogenomic Genome-wide Meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. *Hypertension*. 2016;67(3):556-563. PMID: 26729753. PMCID: PMC4752391.
140. Hamadeh IS, Shahin MH, Lima SM, Oliveira F, Wilson L, Khalifa SI, Langaee TY, **Cooper-DeHoff RM**, Cavallari LH, Johnson JA. Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians. *Clin Transl Sci*. 2016;9(1):36-42. PMID: 26751406. PMCID: PMC4760888.
141. Zhu HJ, Langaee TY, Gong Y, Wang X, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA, Markowitz JS. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. *Eur J Clin Pharmacol*. 2016 ;72(6):681-687. PMID: 26915813. PMCID: PMC4865408.
142. Chang SW, Gong Y, McDonough CW, Langaee TY, Nasiri Kenari N, Beitelshees AL, Gums JG, Chapman AB, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is there a Correlation? *Clin Trans Sci*. 2016; (2):114-122. PMID: 26946962. PMCID: PMC4915567.
143. Ben S, **Cooper-DeHoff RM,** Flaten HK, Evero O, Ferrara TM, Spritz RA, Monte AA. Multiplex SNaPshot – a new simple and efficient CYP2D6 and ADRB1 genotyping method. *Human Genomics.* 2016;10:11. DOI 10.1186/s40246-016-0073-3. PMID: 27108086. PMCID: PMC4842286.
144. Merz CN, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip DE, **Cooper-DeHoff RM**, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. *J Women's Health*. 2016;25(9):875-881. PMID: 27267867. PMCID: PMC5311460.
145. Smith SM, Huo T, Gong Y, Handberg E, Gulati M, Merz CN, Pepine CJ, **Cooper-DeHoff RM**. Mortality Risk Associated with Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. *J Women's Health*. 2016; 25(10):996-1003. PMID: 27224417. PMCID: PMC5069707.
146. de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, **Cooper-DeHoff RM**. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. *Metabolomics*. 2016;12(8):129. PMID: 28217400. PMCID: PMC5310671.
147. Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, **Cooper-DeHoff RM**. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. *Metabolomics*. 2016;12(10):160. PMID: 28217401. PMCID: PMC5313050.
148. Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshees AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, **Cooper-DeHoff RM**, Kaddurah-Daouk R, Johnson JA. A Genetic Response Score for

Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. *Hypertension*. 2016;68(3):621-629. PMID: 27381900. PMCID: PMC4982802.

149. Gharaibeh KA, Turner ST, Hamadah AM, Chapman AB, **Cooper-DeHoff RM**, Johnson JA, Gums JG, Bailey KR, Schwartz GL. Comparison of Blood Pressure Control rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. *Am J Hypertens*. 2016; 29(10):1186-1194. PMID: 27365079. PMCID: PMC5863787.
150. Elgendy IY, Bavry AA, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Long-Term Mortality in Hypertensive Patients with Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study. *Hypertension.* 2016;68(5):1110-1114. PMID: 27620390. PMCID: PMC5063713.
151. Kawaguchi-Suzuki M, Nasiri-Kenari N, Shuster J, Gmitter FG Jr, Cancalon P, de Oliveria F, Kight J, Handberg EM, Pepine CJ, Frye RF, **Cooper-DeHoff RM**. Effect of Low-Furanocoumarin Hybrid Grapefruit Juice consumption on Midazolam Pharmacokinetics. *J clin Pharmacol*. 2017; 57(3):305-311. PMID: 27503364. PMCID: PMC5299073.
152. Salvi E, Wang Z, Rizzi F, Gong Y, McDonough CW, Padmanabhan S, Hiltunen TP, Lanzani C, Zaninello R, Chittani M, Bailey KR, Sarin A-P, Barcella M, Melander O, Chapman AB, Manunta P, Kontula KK, Glorioso N, Cusi D, Dominiczak AF, Johnson JA, Barlassina C, Boerwinkle E, **Cooper-DeHoff RM** and Turner ST. Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. *Hypertension.* 2017; 69(1):51-59. PMID: 27802415. PMCID: PMC5145728.
153. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, **Cooper-DeHoff RM**, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program. "The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems". *Clin Pharmacol Ther*. 2017; 102(3):502-510. PMID: 28090649. PMCID: PMC5511786.
154. Shahin MH, Sá AC, Webb A, Gong Y, Langaee T, McDonough CW, Riva A, Beitleshees AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Scherer SE, Sadee W, **Cooper-DeHoff RM** and Johnson JA. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. *Circulation: Cardiovascular Genetics.* 2017; 10(1):e001404. PMID: 28115488. PMCID: PMC5298887.
155. Dumitrescu L, Ritchie MD, Denny JC, El Rouby NM, McDonough CW, Bradford Y, Ramirez AH, Bielinski SJ, Basford MA, Chai HS, Peissig P, Carrell D, Pathak J, Rasmussen LV, Wang X, Pacheco JA, Kho AN, Hayes MG, Matsumoto M, Smith ME, Li R, **Cooper-DeHoff RM**, Kullo IJ, Chute CG, Chisholm RL, Jarvik GP, Larson EB, Carey D, McCarty CA, Williams MS, Roden DM, Bottinger E, Johnson JA, de Andrade M, Crawford DC. Genome-wide study of resistant hypertension identified from electronic health records. *PLoS One*. 2017;12(2):e0171745. PMID: 28222112. PMCID: PMC5319785.
156. Sperber NR, Carpenter JS, Cavallari LH, J Damschroder L, **Cooper-DeHoff RM**, Denny JC, Ginsburg GS, Guan Y, Horowitz CR, Levy KD, Levy MA, Madden EB, Matheny ME, Pollin TI, Pratt VM, Rosenman M, Voils CI, W Weitzel K, Wilke RA, Ryanne Wu R, Orlando LA. Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. *BMC Med Genomics.* 2017;10(1):35. PMID: 28532511. PMCID: PMC5441047.
157. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS,

Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, **Cooper-DeHoff R**, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium., Krämer BK, Scharnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol*. 2017; 5(7):534-543. PMID: 28566218. PMCID: PMC5651679.

158. Isanejad M, LaCroix AZ, Thomson CA, Tinker L, Larson JC, Qi Q, Qi L, **Cooper-DeHoff RM**, Phillips LS, Prentice RL, Beasley JM. Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women's Health Initiative. *Br J Nutr*. 2017;117(11):1523-1530. PMID: 28721839.
159. Sá ACC, Webb A, Gong Y, McDonough CW, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, **Cooper-DeHoff RM**, Sadee W, Johnson JA. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. *Sci Rep.* 2017; 22;7(1):16068. PMID: 29167564. PMCID: PMC5700078.
160. Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Johnson JA, Turner ST, **Cooper-DeHoff RM**. Blood Pressure Response to Metoprolol and Chlorthalidone in Hypertensive European and African Americans. *Journal of Clinical Hypertension (Greenwhich).* 2017; 19(12):1301-1308. PMID: 28940643. PMCID: PMC5722670.
161. Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. Genetic Variants Associated with Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. *J Am Heart Assoc.* 2017;6(11):e006522. PMID: 29097388. PMCID: PMC5721751.
162. Chang SW, McDonough CW, Gong Y, Johnson TA, Tsunoda T, Gamazon ER, Perera MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. *Pharmacogenomics J*. 2018;18(1):106-112. PMID: 27670767. PMCID: PMC5368017.
163. Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, **Cooper-DeHoff RM**, Han X, Kaddurah-Daouk R, Johnson JA. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights from Genomics, Metabolomics, and Lipidomics. *J Am Heart Assoc.* 2018;7(1):pii:e006656. PMID: 29288159. PMCID: PMC5778957.
164. Wokhlu A*, Smith SM*, Gong Y, Handberg EM, Elgendy IY, Bavry AA, **Cooper-DeHoff RM***, Pepine CJ*. Mortality Implications of Lower DBP with Lower Achieved Systolic Pressures in Coronary Artery Disease: Long-Term Mortality Results from the INternational VErapamil-trandolapril STudy U.S. Cohort. *J Hypertens*. 2018;36(2):419-427. *These authors contributed equally to this work. PMID: 28938338.
165. Cavallari LH, Lee CR, Beitelshees AL, **Cooper-DeHoff RM**, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD,

Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA on behalf of the IGNITE Network. Multisite Investigation of Outcomes with Implementation of *CYP2C19* Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *JACC: Cardiovasc Interv.* 2018;11(2):181-191. PMID: 29102571. PMCID: PMC5775044.

166. Smith SM, McAuliffe K, Hall JM, McDonough CW, Gurka MJ, Robinson TO, Sacco RL, Pepine C, Shenkman E, **Cooper-DeHoff RM**. Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network. *Prev Chronic Dis.* 2018;15:E27. PMID: 29494332. PMCID: PMC5833311.
167. Shahin MH, Conrado DJ*, Gonzalez D*, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers. *J Am Heart Assoc*. 2018;7(5):e006463. *These authors contributed equally to this work. PMID: 29478026. PMCID: PMC5866313.
168. Singh S, McDonough CW, Gong Y, Alghamdi W, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome wide association study identifies the *HMGCS2* locus to be associated with chlorthalidone induced glucose increase in hypertensive patients. *J Am Heart Assoc*. 2018;7(6).pii:e007339. PMID: 29523524. PMCID: PMC5907544.
169. Gong Y, Smith SM, Handberg EM, Pepine CJ, **Cooper-DeHoff RM**. Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. *J Clin Hypertens (Greenwich)*. 2018;20(4):620-624. PMID: 29532983.
170. McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, **Cooper-DeHoff RM**, Gong Y, Johnson JA. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). *Circ Genom Precis Med*. 2018;11(4):e001854. PMID: 29650764. PMCID: PMC5901893.
171. Wenger NK, Arnold A, Bairey Merz CN, **Cooper-DeHoff RM**, Ferdinand KC, Fleg JL, Gulati M, Isiadinso I, Itchhaporia D, Light-McGroary K, Lindley KJ, Mieres JH, Rosser ML, Saade GR, Walsh MN, Pepine CJ. Hypertension Across a Woman's Life Cycle. *J Am Coll Cardiol*. 2018;71(16):1797-181. PMID: 29673470. PMCID: PMC6005390 (Available on 2019-04-24).
172. Ebied AM, **Cooper-DeHoff RM.** 2017 is Banner Year for Drug Approvals by the FDA. *Am J Med.* 2018;131(9):1025-1033. PMID: 29626430.
173. Sá ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, **Cooper-DeHoff RM**, Sadee W, Johnson JA. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. *BMC Medical Genomics*. 2018;11:55. PMID: 29925376. PMCID: PMC6011347.
174. Park K, Egelund E, Huo T, Bairey Merz CN, Handberg EM, Johnson BD, Sopko G, **Cooper-DeHoff RM**, Pepine CJ. Serotonin Transporter Gene Polymorphism in Women With Suspected Ischemia: A Report From the NHLBI-Sponsored WISE. *Gender and the Genome*. 2018;2(1):8-15. DOI: 10.1177/2470289718787114.

175. Filipp SL, Cardel M, Hall J, Essner RZ, Lemas DJ, Janicke DM, Smith SR, Nadglowski J, Troy Donahoo W, **Cooper-DeHoff RM**, Nelson DR, Hogan WR, Shenkman EA, Gurka MJ. Characterization of adult obesity in Florida using the OneFlorida clinical research consortium. *Obesity Science & Practice*. 2018;4:308–317. PMID: 30151226. PMCID: PMC6105705.
176. Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, **Cooper-DeHoff RM**. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. *Am J Med*. 2018;131(12):1463-1472.e7. PMID: 30142317. PMCID: PMC6279479 (Available on 2019-12-01).
177. El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Crawford DC; eMERGE network, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, **Cooper-DeHoff RM**, Benavente OR, Shuldiner AR, Johnson JA. Genome-wide association analysis of common genetic variants of resistant hypertension. *Am J Med*. 2019 Jun;19(3):295-304. PMID: 30237584. PMCID: PMC6426691 (Available on 2020-06-01)
178. Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, Turner ST, Chapman AB, Gums JG, McDonough CW, Bailey KR, Beitelshees AL, **Cooper-DeHoff RM**, Scherer S, Boerwinkle E, Johnson JA. Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. *Pharmacogenetics and Genomics.* 2018;28(11):251-255. PMID: 30289819. PMCID PMC6262886 (Available on 2019-11-01).
179. Smith SM, **Cooper-DeHoff RM**. Fixed-dose combination amlodipine/celecoxib (Consensi™) for hypertension and osteoarthritis. *Am J Med*. 2019;132(2):172-174. PMID: 30240679.
180. Lemas DJ, Cardel MI, Filipp SL, Hall J, Essner RZ, Smith SR, Nadglowski J, Donahoo WT, **Cooper-DeHoff RM**, Nelson DR, Hogan WR, Shenkman EA, Gurka MJ, Janicke DM. Objectively Measured Pediatric Obesity Prevalence Using the OneFlorida Clinical Research Consortium. *Obesity Research & Clinical Practice*. 2019;13(1):12-15. PMID: 30391132.
181. Magvanjav O, **Cooper-DeHoff RM**, McDonough CW, Gong Y, Segal MS, Hogan WR, Johnson JA. Antihypertensive Therapy Prescribing Patterns and Correlates of Blood Pressure Control Among Hypertensive Patients with Chronic Kidney Disease. *J Clin Hypertens (Greenwich)*. 2019;21(1):91–101. PMID: 30427124. PMCID: PMC6329007 (Available on 2020-01-01).
182. Solayman MH, Langaee TY, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshees AL, El-Hamamsy M, El-Wakeel L, **Cooper-DeHoff RM**, Badary OA, Johnson JA. Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. *Eur J Pharm Sci*. 2019;131:93-98. PMID: 30753892.
183. Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, **Cooper-DeHoff RM**. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. *Am J Hypertens*. 2019 Jun;32(7):668-675. PMID: 30753254.
184. Singh S, Alghamdi W, Arwood M, Bargal S, de Oliverira F, Dumeny L, Li W, Mehanna M, Fredette N, Stockard B, Yang G, Shahin M, Bailey KR, Beitelshees AL, Boerwinkle B, Chapman AB, Gums JG, Turner ST, Gong Y, McDonough CW, **Cooper-DeHoff RM**, Johnson JA. Genome Wide Association Study to Identify Pharmacogenomic variants associated with Chlorthalidone Induced glucose change in African Americans. *J Am Heart Assoc*. 2019. In Press.
185. Ebied AM, Na J, **Cooper-DeHoff RM**. New Drug Approvals in 2018 – Another Record Year! *Am J Med*. 2019; pii: S0002-9343(19)30219-0. doi: 10.1016/j.amjmed.2019.02.024. PMID: 30853471. (Epub ahead of print).

186. Patel R, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots M, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, **Cooper-DeHoff RM**, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Paré G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW. Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. *Circ Genom Precis Med*. 2019. PMID: 30896328 (Epub ahead of print).

187. Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, **Cooper-DeHoff RM**, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J, Van der Harst P, Tardif JC, Sattar N, Lang CC, Paré G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron

VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW. Association of Chromosome 9p21 with Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data. *Circ Genom Precis Med*. 2019. PMID: 30897348 (Epub ahead of print).

188. Singh S, El Rouby N, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genomic Association Analysis Reveals Variants Associated with Blood Pressure Response to Beta-Blockers in European Americans. *Clinical and Translational Science*. 2019Apr 29. doi: 10.1111/cts.12643. PMID: 31033190 (Epub ahead of print).
189. Borja-Hart N, Graff JC, Nolan VG, Wang J, **Cooper-DeHoff RM**, Ancheta IB. Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipino-American Women. *J Clin Pharm Ther*. 2019 Apr 8. PMID: 30963623 (Epub ahead of print).
190. Chamberlain AM, Gong Y, Shaw KM, Bian J, Song WL, Linton MF, Fonseca V, Price-Haywood E, Guhl E, King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez AF, **Cooper-DeHoff RM**. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. *J Am Heart Assoc*. 2019 May 7;8(9):e011246. PMID: 31020929.
191. Smith SM, Gurka MJ, Winterstein AG, Pepine CJ, **Cooper-DeHoff RM**. Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering. *J Clin Hypertens (Greenwich)*. 2019 Jun;21(6):825-834. doi: 10.1111/jch.13550. PMID: 31066177. PMCID: PMC6565478 [Available on 2020-06-01].
192. Shahin MH, Rouby NE, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence from 3 Clinical Studies. *J Clin Pharmacol*. 2019 May 14. doi: 10.1002/jcph.1443. PMID: 31090079 (Epub ahead of print).
193. Singh S, McDonough CW, Gong Y, Bailey K, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Scientific Reports. 2019, In Press.
194. Iniesta R, Campbell D, Venturini C, Faconti L, Singh S, Irvin MR, **Cooper-DeHoff RM**, Johnson JA, Turner ST, Arnett DK, Weale ME, Warren H, Munroe PB, Cruickshank K, Padmanabhan S, Lewis C, Chowienczyk P. Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals. Hypertension. 2019 Sep;74(3):614-622. doi: 10.1161/HYPERTENSIONAHA.118.12177. Epub 2019 Jul 22. PubMed PMID: 31327267.
195. Sava RI, Chen YE, Smith SM, Gong Y, **Cooper-DeHoff RM**, Keeley EC, Pepine CJ, Handberg EM. Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The International VErapamil SR-Trandolapril STudy (INVEST). J Womens Health (Larchmt). 2020 Feb;29(2):158-166. doi: 10.1089/jwh.2018.7235. Epub 2019 Aug 12. PubMed PMID: 31403360.
196. Singh S, Warren HR, Hiltunen TP, McDonough CW, El Rouby N, Salvi E, Wang Z, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, Gong Y, **Cooper-DeHoff RM**. Genome-Wide Meta-Analysis of Blood Pressure Response to β(1)-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 Aug 20;8(16):e013115. doi: 10.1161/JAHA.119.013115. Epub 2019 Aug 19. PubMed PMID: 31423876; PubMed Central PMCID: PMC6759913.
197. Cunningham PN, Wang Z, Grove ML, **Cooper-DeHoff RM**, Beitelshees AL, Gong Y, Gums JG, Johnson JA, Turner ST, Boerwinkle E, Chapman AB. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin

receptor blockade compared to low risk carriers. PLoS One. 2019 Sep 18;14(9):e0221957. doi: 10.1371/journal.pone.0221957. eCollection 2019. PubMed PMID: 31532792; PubMed Central PMCID: PMC6750571.

198. Singh S, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 Nov 21;9(1):17323. doi: 10.1038/s41598-019-53345-5. PubMed PMID: 31754133; PubMed Central PMCID: PMC6872535.
199. Elgendy IY, Hill JA, Szady AD, Gong Y, **Cooper-DeHoff RM**, Pepine CJ. Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Fail. 2020 Feb;7(1):123-129. doi: 10.1002/ehf2.12534. Epub 2019 Dec 15. PubMed PMID: 31840441; PubMed Central PMCID: PMC7083485.
200. Magvanjav O, **Cooper-Dehoff RM**, McDonough CW, Gong Y, Hogan WR, Johnson JA. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. Am J Hypertens. 2020 Apr 1;33(4):316-324. doi: 10.1093/ajh/hpz196. PubMed PMID: 31853537; PubMed Central PMCID: PMC7109351.
201. Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, **Cooper-Dehoff RM**. Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. Am J Hypertens. 2020 Feb 22;33(2):e2. doi: 10.1093/ajh/hpz168. PubMed PMID: 31891170.
202. Smith SM, Gurka MJ, Winterstein AG, Handberg E, Pepine CJ, **Cooper-DeHoff RM**. Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension. Circ Cardiovasc Qual Outcomes. 2020 Feb;13(2):e005979. doi: 10.1161/CIRCOUTCOMES.119.005979. Epub 2020 Feb 3. PubMed PMID: 32008359; PubMed Central PMCID: PMC7006690.
203. Smith SM, Winterstein AG, Pepine CJ, **Cooper-DeHoff RM**. Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification. Hypertension. 2020 Mar;75(3):e2-e5. doi: 10.1161/HYPERTENSIONAHA.119.14447. Epub 2020 Feb 3. PubMed PMID: 32008437; PubMed Central PMCID: PMC7035168.
204. McDonough CW, Smith SM, **Cooper-DeHoff RM**, Hogan WR. Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison. JMIR Med Inform. 2020 Feb 27;8(2):e14777. doi: 10.2196/14777. PubMed PMID: 32130152; PubMed Central PMCID: PMC7068459.
205. Pletcher MJ, Fontil V, Carton T, Shaw KM, Smith M, Choi S, Todd J, Chamberlain AM, O'Brien EC, Faulkner M, Maeztu C, Wozniak G, Rakotz M, Shay CM, **Cooper-DeHoff RM**. The PCORnet Blood Pressure Control Laboratory: A Platform for Surveillance and Efficient Trials. Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006115. doi: 10.1161/CIRCOUTCOMES.119.006115. Epub 2020 Mar 6. PubMed PMID: 32142371.
206. Ebied AM, Patel KH, **Cooper-DeHoff RM**. New Drugs Approved in 2019. Am J Med. 2020 Mar 5. pii: S0002-9343(20)30141-8. doi: 10.1016/j.amjmed.2020.01.030. [Epub ahead of print] Review. PubMed PMID: 32145207.
207. Yang J, Asico LD, Beitelshees AL, Feranil JB, Wang X, Jones JE, Armando I, Cuevas SG, Schwartz GL, Gums JG, Chapman AB, Turner ST, Boerwinkle E, **Cooper-DeHoff RM**, Johnson JA, Felder RA, Weinman EJ, Zeng C, Jose PA, Villar VAM. Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB J. 2020 Apr 15. doi: 10.1096/fj.201902448R. [Epub ahead of print] PubMed PMID: 32293069.
208. Marrero RJ, Cicali EJ, Arwood MJ, Eddy E, DeRemer D, Ramnaraign BH, Daily KC, Jones D Jr, Cavallari LH, Wiisanen KW, Langaee T, Newsom KJ, Starostik P, Clare-Salzer MJ, Johnson JA, George TJ, **Cooper-DeHoff RM**. How to Transition from Single Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial. *Clin*

Pharmacol Ther. 2020 May 27. doi: 10.1002/cpt.1912. [Epub ahead of print]. PMID: 32460360

209. Mahmoodi BK, Tragante V, Kleber ME, Holmes MV, Schmidt AF, McCubrey RO, Howe LJ, Direk K, Allayee H, Baranova EV, Braund PS, Delgado GE, Eriksson N, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Pasterkamp G, Kotti S, Kuukasjärvi P, Lenzini PA, Levin D, Lyytikäinen LP, Muehlschlegel JD, Nelson CP, Nikus K, Pilbrow AP, Tang WHW, van der Laan SW, van Setten J, Vilmundarson RO, Deanfield J, Deloukas P, Dudbridge F, James S, Mordi IR, Teren A, Bergmeijer TO, Body SC, Bots M, Burkhardt R, **Cooper-DeHoff RM**, Cresci S, Danchin N, Doughty RN, Grobbee DE, Hagström E, Hazen SL, Held C, Hoefer IE, Hovingh GK, Johnson JA, Kaczor MP, Kähönen M, Klungel OH, Laurikka JO, Lehtimäki T, Maitland-van der Zee AH, McPherson R, Palmer CN, Kraaijeveld AO, Pepine CJ, Sanak M, Sattar N, Scholz M, Simon T, Spertus JA, Stewart AFR, Szczeklik W, Thiery J, Visseren FLJ, Waltenberger J, Richards AM, Lang CC, Cameron VA, Åkerblom A, Pare G, März W, Samani NJ, Hingorani AD, Ten Berg JM, Wallentin L, Asselbergs FW, Patel R. Association of Factor V Leiden with Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. Circulation. 2020 Jul 13. doi: 10.1161/CIRCULATIONAHA.119.045526. [Epub ahead of print] PMID: 32654539
210. Sava RI, Chen YE, Smith SM, Gong Y, **Cooper-DeHoff RM**, Keeley EC, Pepine CJ, Handberg EM. Risk and Blood Pressure Control Rates Across the Specturm of Coronary Artery Disease in Hypertensive Women: An Analysis from the International Verapamil SR-Trandolapril Study (INVEST). J Womens Health (Larchmt). 2020 Feb;29(2):158-166. doi: 10.1089/jwh.2018.7235. Epub 2019 Aug 12. PMID: 31403360
211. Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, **Cooper-DeHoff RM**, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.Association of Chromosome 9p21 Subsequent Coronary Heart Disease Events. Circ Genom Precis Med. 2019 Apr;12(4):e002471. doi: 10.1161/CIRCGEN.119.002471. Epub 2019 Mar 21. PMID: 30897348
212. McDonough CW, Babcock K, Chucri K, Crawford DC, Bian J, Modave F, **Cooper-DeHoff RM**, Hogan WR. Optimizing identification of resistant hypertension: Computable phenotype development and validation. *Pharmacoepidemiology and Drug*

Safety. 2020 Nov;29(11):1393-1401. doi: 10.1002/pds.5095. Online ahead of print. PMID: 32844549.

213. Collins KS, Raviele ALJ, Elchynski AL, Woodcock AM Zhao Y, **Cooper-DeHoff RM**, Eadon MT. Genotype-Guided Hydralazine Therapy. Am J Nephrol. 2020:51(10):764-776. PMID:32927458
214. Keeley EC, Villanueva M, Chen YE, Gong Y, Handberg EM, Smith SM, Pepine CJ, **Cooper-DeHoff RM**. Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. J Clin Hypertens. 2020:22(11);1987-1992. PMID: 32951360
215. Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee TY, Gong Y, Wang D, Schmidt SO, Binkley PF, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman AB, **Cooper-DeHoff RM**, Gums JG, Hamadeh IS, Zhao L, Schmidt S, Frye RF, Johnson JA, Cavallari LH. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores. CPT Pharmacometrics Syst Pharmacol 2020 Dec 9(12):678-685. PMID**:** 33067866.
216. Sava RI, Smith SM, Chen Y, Taha Y, Gong Y, Keeley EC, **Cooper-Dehoff RM**, Pepine CJ, Handberg EM. Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – an analysis from INVEST. *Int J Cardiol Hypertens*. 2020 16;7:100052. doi: 10.1016/j.ijchy.2020.100052. eCollection 2020 Dec. PMID: 33817619.
217. Waheed N, Fradley MG, DeRemer D, Mahmoud A, Shah CP, Langaee TY, Lipori GP, March K, Pepine CJ, **Cooper-DeHoff RM**, Wu Y, Gong Y. Newly diagnosed cardiovascular disease in patients treated with Immune Checkpoint Inhibitors: A retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology. 2021 Mar doi: 10.1186/s40959-021-00097-9. PMID**:** 33736707
218. Mehanna M, Chen YE, Gong Y, Handberg E, Roth B, De Leon J, Smith SM, Harrell JG, **Cooper-DeHoff RM.** Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing. Clin Transl Sci 2021:14(2)617-624. PMID: 33142006.
219. Bargal SA, Kight JN, Augusto de Oliveira F, Shahin MH, Langaee T, Gong Y, Hamadeh IS, **Cooper-DeHoff RM**, Cavallari LH. Implications of polymorphisms in the BCKDK and GATA-4 gene regions on stable warfarin dose in African Americans. Clin Transl Sci 2021 14(2) 492-496. PMID: 33278335.
220. Handberg EM, Bairey Merz CN, **Cooper-Dehoff RM**, Wei J, Conlon M, Lo MC, Boden W, Frayne SM, Villines T, Spertus JA, Weintraub W, O'Malley P, Chaitman B, Shaw LJ, Budoff M, Rogatko A, Pepine CJ. Rationale and design of the Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR) Trial. *Am Heart J.*2021;237:90-103. PMID: 33745898.
221. Dasa O, Smith SM, Howard G, **Cooper-DeHoff RM**, Gong Y, Handberg E, Pepine CJ. Association of 1-year blood pressure variability and long-term mortality among adults with coronary artery disease: a post hoc analysis of a rancomized clinical trial. *JAMA Netw Open*. 2021;4(4):e218418. doi: 10.1001/jamanetworkopen.2021.8418. PMID: 33914047.
222. Waheed N, Fradley MG, DeRemer DL, Mahmoud A, Shah CP, Langaee TY, Lipori GP, March K, Pepine CJ, **Cooper-DeHoff RM**, Wu Y, Gong Y. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021 Mar 18;7(1):10. doi: 10.1186/s40959-021-00097-9. PMID: 33736707.
223. Chekka LMS, Chapman AB, Gums JG, **Cooper-DeHoff RM**, Johnson JA. Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med 2021;134(7):918-925. PMID: 33434556.
224. Schunk SJ, Kleber ME, März W, Pang S, Zewinger S, Triem S, Ege P, Reichert MC, Krawczyk M, Weber SN, Jaumann I, Schmit D, Sarakpi T, Wagenpfeil S, Kramann R,

Boerwinkle E, Ballantyne CM, Grove ML, Tragante V, Pilbrow AP, Richards AM, Cameron VA, Doughty RN, Dubé MP, Tardif JC, Feroz-Zada Y, Sun M, Liu C, Ko YA, Quyyumi AA, Hartiala JA, Tang WHW, Hazen SL, Allayee H, McDonough CW, Gong Y, **Cooper-DeHoff RM**, Johnson JA, Scholz M, Teren A, Burkhardt R, Martinsson A, Smith JG, Wallentin L, James SK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Campbell H, Tierling S, Walter J, Ampofo E, Niemeyer BA, Lipp P, Schunkert H, Böhm M, Koenig W, Fliser D, Laufs U, Speer T; eQTLGen consortium; BIOS consortium. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021;42(18):1742-1756. PMID: 33748830.

225. Ginsburg GS, Cavallari LH, Chakraborty H, **Cooper-DeHoff RM**, Dexter PR, Eadon MT, Ferket BS, Horowitz CR, Johnson JA, Kannry J, Kucher N, Madden EB, Orlando LA, Parker W, Peterson J, Pratt VM, Rakhra-Burris TK, Ramos MA, Skaar TC, Sperber N, Steen-Burrell KA, Van Driest SL, Voora D, Wiisanen K, Winterstein AG, Volpi S; IGNITE PTN. Genet Med. 2021; Jul;23(7):1185-1191. doi: 10.1038/s41436-021-01118-9. Online ahead of print. PMID: 33782552.
226. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, **Cooper-DeHoff RM**, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19 related outcomes among US Veterans. PLoS One 2021;16(4):e0248080. doi: 10.1371/journal.pone.0248080. eCollection 2021. PMID: 33891615.
227. Ebied AM, Elmariah H, **Cooper-DeHoff RM**. New Drugs Approved in 2020.Am J Med 2021; Apr 30:S0002-9343(21)00276-X. doi:10.1016/j.amjmed.2021.03.034. Online ahead of print. PMID: 33939997.
228. Schneider TM, Eadon MT, **Cooper-DeHoff RM**, Cavanaugh KL, Nguyen KA, Arwood MJ, Tillman EM, Pratt VM, Dexter PR, McCoy AB, Orlando LA, Scott SA, Nadkarni GN, Horowitz CR, Kannry JL. Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management. J Pers Med. 2021; May 27;11(6):480. doi: 10.3390/jpm11060480. PMID: 34071920.
229. Holmes HR, Li Q, Xu K, Seungbum K, Richards EM, Keeley EC, Handberg EM, Smith SM, Raizada MK, Pepine CJ, **Cooper-DeHoff RM**. Antihyperetensive medication adherence trends by sex and drug class: A pilot study. Am Heart Journal Plus: Cardiology Research and Practice 2021; https://doi.org/10.1016/j.ahjo.2021.100023
230. McDonough CW, Warren HR, Jack JR, Motsinger-Reif AA, Armstrong ND, Bis JC, House JS, Singh S, El Rouby NM, Gong Y, Mychaleckyj JC, Rotroff DM, Benavente OR, Caulfield MJ, Doria A, Pepine CJ, Psaty BM, Glorioso V, Glorioso N, Hiltunen TP, Kontula KK, Arnett DK, Buse JB, Irvin MR, Johnson JA, Munroe PB, Wagner MJ, **Cooper-DeHoff RM**. Adverse Cardiovascular Outcomes and Antihypertensive treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS). Clin Pharmacol Ther. 2021 Sep;110(3):723-732. doi: 10.1002/cpt.2355. Epub 2021 Aug 15. PMID: 34231218
231. Pepine CJ, Thiel A, Kim S, Handberg EM, Richards EM, Dasa O, Mohammed M, Smith SM, **Cooper-DeHoff RM**, Raizada MK. Potential of Minocycline for Treatment of Resistant Hypertension. Am J Cardiol 2021 Online ahead of Print PMID:34348841.
232. Mehanna M, McDonough CW, Smith SM, Gong Y, Gums JG, Chapman AB, Johnson JA, McIntyre L, **Cooper-DeHoff RM**. Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. *Metabolites*. 2021; 11(9):645. https://doi.org/10.3390/metabo11090645
233. **Cooper-DeHoff RM**, Fontil V, Carton T, Chamberlain AM, Todd J, O'Brien EC, Shaw KM, Smith M, Choi S, Nillis EK, Ford D, Tecson KM, Dennar PE, Ahmad F, Wu S,

McClay JC, Azar K, Singh R, Faulkner Modrow M, Shay CM, Rakotz M, Wozniak G, Pletcher MJ. Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory. *J Am Heart Assoc.* 2021; Oct 6:e022224. doi: 10.1161/JAHA.121.022224. PMID: 34612048

234. Smith SM, Desai R, Walsh MG, Nilles EK, Shaw K, Smith M, Chamberlain AM, Derington CG, Bress AP, Chuang CH, Ford DE, Taylor BW, Chandaka S, Patel LP, McClay J, Priest E, Fuloria J, Doshi K, Ahmad FS, Viera AJ, Faulkner M, O'Brien EC, Pletcher MJ, **Cooper-DeHoff RM**. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19 severity: A patient-level analysis of the PCORnet blood pressure control lab. *Am Heart J Plus* 2022;13:100112. PubMed ID: 35252907
235. Eadon MT, Cavanaugh KL, Orlando LA, Christian D, Chakraborty H, Steen-Burrell KA, Merrill P, Seo J, Hauser D, Singh R, Beasley CM, Fuloria J, Kitzman H, Parker AS, Ramos M, Ong HH, Elwood EN, Lynch SE, Clermont S, Cicali EJ, Starostik P, Pratt VM, Nguyen KA, Rosenman MB, Calman NS, Robinson M, Nadkarni GN, Madden EB, Kucher N, Volpi S, Dexter PR, Skaar TC, Johnson JA, **Cooper-DeHoff RM***, Horowitz CR* (*co-senior authors); GUARDD-US Investigators. Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. Contemp Clin Trials. 2022 Jun 1;119:106813. doi: 10.1016/j.cct.2022.106813. Online ahead of print. PMID: 35660539.
236. Dungan, J. R.**,** Qin, X., Gregory S. G., **Cooper-DeHoff, RM**., Duarte, J. D., Qin, H., Gulati, M., Taylor, J. Y., Pepine, C. J., Hauser, E. R., & Kraus, W. E. Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease (June 2022, In Press). *American Heart Journal Open: Cardiology Research and Practice.* 100152. Available as pre-print online via: https://doi.org/10.1016/j.ahjo.2022.100152.
237. Schillemans T, Tragante V, Maitusong B, Gigante B, Cresci S, Laguzzi F, Vikström M, Richards M, Pilbrow A, Cameron V, Foco L, Doughty RN, Kuukasjärvi P, Allayee H, Hartiala JA, Tang WHW, Lyytikäinen LP, Nikus K, Laurikka JO, Srinivasan S, Mordi IR, Trompet S, Kraaijeveld A, van Setten J, Gijsberts CM, Maitland-van der Zee AH, Saely CH, Gong Y, Johnson JA, **Cooper-DeHoff RM**, Pepine CJ, Casu G, Leiherer A, Drexel H, Horne BD, van der Laan SW, Marziliano N, Hazen SL, Sinisalo J, Kähönen M, Lehtimäki T, Lang CC, Burkhardt R, Scholz M, Jukema JW, Eriksson N, Åkerblom A, James S, Held C, Hagström E, Spertus JA, Algra A, de Faire U, Åkesson A, Asselbergs FW, Patel RS, Leander K. Associations of polymorphisisms in the peroxisome proliferator-activated receptor gamma coactivator-I alpha gene with subsequent coronary heart disease: an individual-level meta-analysis. *Front Physiol* 2022 Jun 23;13:909870. doi: 10.3389/fphys.2022.909870. eCollection 2022. PMID: 35812313
238. Ebied AM, Elmariah H, **Cooper-DeHoff RM**. New Drugs Approved in 2021. *Am J Med*. 2022 Jul;135(7):836-839. doi: 10.1016/j.amjmed.2022.01.055. Epub 2022 Feb 27. PMID: 35235820
239. Grande KJ, Dalton R, Moyer NA, Arwood MJ, Nguyen KA, Sumfest J, Ashcraft KC, **Cooper-DeHoff RM**. Assessment of a manual method versus an automated, probability-based algorithm to identify patients at high risk for pharmacogenomic adverse drug outcomes in a university-based health insurance program. *J Pers Med*. 2022 Jan 26;12(2):161. doi: 10.3390/jpm12020161. PMID: 35207649
240. **Cooper-DeHoff RM**, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *SLCO1B1, ABCG2* and *CYP2C9* genotypes and statin-assoaciated musculoskeletal symptoms. *Clin Pharmacol Ther*. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405.

241. Smith SM, **Cooper-DeHoff RM**. Acetominophen-Induced Hypertension: Where Have All the “Safe” Analgesics Gone? *Circulation*. 2022 Feb 8;145(6):424-426. doi: 10.1161/CIRCULATIONAHA.121.058068. Epub 2022 Feb 7. PMID: 35130051.
242. Mehanna M, McDonough CW, Smith SM, Gong Y, Gums JG, Chapman AB, Johnson JA, **Cooper-DeHoff RM**. Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients. Metabolites. 2022 Aug 24;12(9):783.
243. Pletcher MJ; Fontil V; Modrow MF; Carton T; Chamberlain AM; Todd J; O’Brien EC; Sheer A; Vittinghoff E; Park S; Orozco J; Lin F; Maeztu C; Wozniak G; Rakotz M; Shay CM; **Cooper-DeHoff RM**. Effectiveness of standard versus enhanced self-measurement of blood pressure paired with a connected smartphone application: A randomized controlled trial. *JAMA Intern Med* 2022; Oct 1; 182(10):1025-1034. doi: 10.1001/jamainternmed.2022.3355. Online ahead of print. PMID: 35969408.
243. Armstrong ND, Srinivasasainagendra V, Chekka LMS, Nguyen NHK, Nahid NA, Jones AC, Tanner RM, Hidalgo BA, Limdi NA, Claas SA, Gong Y, McDonough CW, **Cooper-DeHoff RM**, Johnson JA, Tiwari HK, Arnett DK, Irvin MR. Genetic Contributions of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Assocated Treatments (GenHAT) Study. *Genes*. 2022 Genes (Basel). 2022 Jul 15;13(7):1260. doi: 10.3390/genes13071260. PMID: 35886043.
244. Chekka LMS, **Cooper-DeHorr RM**, Gums JG, Chapman AB, Johnson JA. Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients. Clin Transl Sci. 2022 Dec;15(12):2858-2867
245. Smith SM, Winterstein AG, Gurka MJ, Walsh MG, Keshwani S, Libby A, Hogan W, Pepine CJ, **Cooper-DeHoff RM**. Initial antihypertensive regimens in newly treated patients: Real world evidence from the OneFlorida Clinical Research Network. J Am Heart Assoc 2023;Jan 3;12:e026652.
246. Fontil V, Modrow MF, **Cooper-DeHoff RM**, Wozniak G, Rakotz M, Todd J, Azar K, Murakami L, Sanders M, Chamberlain AM, O’Brien E, Lee A, Carton T, Pletcher MJ. Improvement in Blood Pressure Control in Saety Net Clinics Receiving 2 Versions of a Scalable Quality Improvement Intervention: BP MAP A Pragmatic Cluster Randomized Trial. J Am Heart Assoc. 2023;Jan 25:e024975.
247. Chamberlain AM, **Cooper-DeHoff RM**, Fontil V, Nilles EK; Shaw KM, Smith M, Lin F, Vittinghoff E, Maeztu C, Todd JV, Carton T, O’Brien EC, Modrow MF, Wozniak G, Rakotz M, Sanchez E, Smith SM, Polonsky TS, Ahmad FS, Liu M, McClay JC, VanWormer JJ, Taylor BW, Chrischilles EC, Wu S, Viera AJ, Ford DE, Hwang W, Knowlton KU, Pletcher MJ. Disruption in Blood Pressure Control With the COVID 19 Pandemic: The PCORnet Blood Pressure Control Laboratory. Mayo Clinic Proceedings. May 2023 98(5):662-675. https://doi.org/10.1016/j.mayocp.2022.12.024
248. Nilles EK, Champon X, Mulder H, Shaw KM, Smith M, Lampron ZM, Wozniak G, Chamberlain AM, Carton T, Viera AJ, Ahmad FS, Steinberg BA, Chuang CH, Mctigue KM, McClay JC, Polonsky TS, Maeztu C, Sanders M, Warren N, Singh R, Liu M, VanWormer JJ, Park S, Modrow MF, Rakotz M, **Cooper-Dehoff RM**, Pletcher MJ, O'Brien EC. Seasonal variation in blood pressure control across US health systems. J Hypertens. 2023. Mar 6. doi: 10.1097/HJH.0000000000003396. Online ahead of print.
249. **Cooper-DeHoff RM** and Smith SM. Medication Adherence – Still the Holy Grail. J Am Heart Assoc. 2023. Feb 21 12(4):e028688. doi: 10.1161/JAHA.122.028688. Epub 2023 Feb 3.
250. Ebied AM, Elmariah H, **Cooper-DeHoff RM.** New Drugs Approved in 2022. Am J Med. 2023. Jun 136(6):545-550.
251. Joseph J, Pajewski NM, Dolor RJ, Sellers MA, Perdue LH, Peeples SR, Henrie AM, Woolard N, Jones WS, Benziger CP, Orkaby AR, Mixon AS, VanWormer JJ, Shapiro MD, Kistler CE, Polonsky TS, Chatterjee R, Chamberlain AM, Forman DE, Knowlton KU, Gill TM, Newby LK, Hammill BG, Cicek MS, Williams NA, Decker JE, Ou J, Rubinstein J, Choudhary G, Gazmuri RJ, Schmader KE, Roumie CL, Vaughan CP, Effron MB, **Cooper-DeHoff RM**, Supiano MA, Shah RC, Whittle JC, Hernandez AF, Ambrosius WT,

Williamson JD, Alexander KP; PREVENTABLE Trial Research Group. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. *J Am Geriatr Soc*. 2023 Apr 20. doi: 10.1111/jgs.18312. Epub ahead of print. PMID: 37082807.

252. Nilles EK, Champon X, Mulder H, Shaw KM, Smith M, Lampron ZM, Wozniak G, Chamberlain AM, Carton T, Viera AJ, Ahmad FS, Steinberg BA, Chuang CH, Mctigue KM, McClay JC, Polonsky TS, Maeztu C, Sanders M, Warren N, Singh R, Liu M, VanWormer JJ, Park S, Modrow MF, Rakotz M, **Cooper-Dehoff RM**, Pletcher MJ, O'Brien EC. Seasonal Variation In Blood Pressure Contro Across Health Systems. J Hypertens. 2023, 41(5):751-758.
253. Chamberlain AM, **Cooper-DeHoff RM**, Pletcher MJ. In Reply: Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients. Mayo Clin Proc 2023 Jun, 98(6):949.
251. DeRemer DL, Nguyen NK, Guha A, Ahmad FS, **Cooper-DeHoff RM**, Pepine CJ, Fradley MG, Gong Y. Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Paitnets Treated With Anthracycline-Based Chemotherapy. J Am Heart Assoc. 2023 May 16;12(10):e027981. doi: 10.1161/JAHA.122.027981. Epub 2023 May 9. PMID: 37158063
252. Lu Y, Keeley EC, Barrette E, **Cooper-DeHoff RM**, Dhruva SS, Gaffney J, Gamble G, Handke B, Huang C, Krumholz HM, McDonough Rowe CW, Schulz W, Shaw K, Smith M, Woodard J, Young P, Ervin K, Ross JS. Use of Electronic Health Records to Characterize Patients wi'th Uncontrolled Hypertension in Two Large Health System Networks. medRxiv. Jul 28:2023.07.26.23293225. doi: 10.1101/2023.07.26.23293225. PMID: 37546792
253. Jafari E, **Cooper-DeHoff RM**, Effron MB, Hogan WR, McDonough CW. Characteristics and Predictors of Apparent Treatment Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data. Am J Hypertens. 2024 Jan 37(1):60-68.
254. Smith KM, Keshwani S, Walsh MG, Winterstein AG, Gurka MJ, Libby A, Hogan WR, Pepine CJ, **Cooper-DeHoff RM**, Smith SM. Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium. Hypertension. 2024 Feb;81(2):e7-e9.
255.

ABSTRACTS:

Peer reviewed abstract presented at national and international meetings

1. Hendeles L, Davison D, Blake K, Harman E, **Cooper RM**, Margolskee D. Leukotriene D_4 is an important mediator of antigen-induced bronchoconstriction: Attenuation of dual response with MK-571, a specific LTD_4 receptor antagonist. *J Allergy Clin Immunol*. 1990; 85(1):197. Presentation at the 46th Annual American Academy of Allergy and Immunology Meeting; March 23-28, 1990; Baltimore, MD.
2. Huang D, Harman E, Friedman B, Tanaka W, **Cooper RM**, Hendeles L. Effect of a leukotriene synthesis inhibitor (MK-886) on the early and late asthmatic response. *Chest* 1990; 98(2 Suppl.):50S. Presentation at the 56th Annual Scientific Assembly American College of Chest Physicians; October 22-26,1990; Toronto, Canada.
3. Pepine CJ, Conlon M, Handberg-Thurmond E, Marks RG, **Cooper-DeHoff RM**, Kolb HR. A 'paper-less' study on optimal treatment strategies for hypertension and CAD: Pilot phase data from the INternational VErapamil-trandolapril STudy (INVEST). *J Am Coll Cardiol*. 1998; 31(Suppl.1):211A. Presentation at the 47th Annual Scientific Sessions of the American College of Cardiology; March 31, 1998; Atlanta GA.
4. **Cooper-DeHoff RM**, Handberg EM, Marks RG, Conlon M, Kolb HR, Bristol H, and Pepine CJ for the INVEST Investigators. Control of blood pressure in a population of

women with hypertension and CAD using an Internet-based electronic prescribing system. *Am J Hypertension*. 2000; 13(S2):117A. Poster presentation at the 15th Scientific Meeting of the American Society of Hypertension; May 16-20, 2000; New York, NY.

5. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Kolb HR, Gaxiola E, Cangiano J, Pepine CJ. Characteristics and blood pressure responses of 6,057 Hispanic hypertensive patients with coronary artery disease enrolled in the INVEST. *J Am Coll Cardiol*. 2001;37(2 Suppl. 1):216A. Poster presentation at the 50th Annual Scientific Session of the American College of Cardiology; March 21, 2001; Orlando, FL.
6. **Cooper-DeHoff RM**, Handberg EM, Bristol H, Kolb M, Keltai R, Kolloch S, Erdine G, Mancia C, Pepine CJ. A comparison of European vs non-European hypertensive patients with co-existing coronary artery disease: An analysis from the total randomized sample of the INVEST. *J Hypertens*. 2001;19(S2):S189. Poster presentation at the 11th European Meeting on Hypertension; June 18, 2001; Milan, Italy.
7. **Cooper-DeHoff RM**, Handberg EM, Bristol H, Kolb H, Pepine CJ. Blood pressure control in a cohort of patients with diabetes and ischemic heart disease. Presentation at the American Heart Association Conference on Molecular, Integrative, and Clinical Approaches to Myocardial Ischemia; August, 9-11, 2001; Seattle, WA.
8. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Pepine CJ, for INVEST Investigators. Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. *Am J Hypertension*. 2002;15(S3):194A. Poster presentation at the 17th Annual Scientific Meeting of the American Society of Hypertension; May 14 - 18, 2002; New York, NY.
9. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Kolb HR, Cangiano J, Cohen JD, Erdine S, Gaxiola E, Keltai M, Kolloch R, Kowey P, Mancia G, Messerli F, Pepine CJ for INVEST Investigators. Characteristics predicting blood pressure responses in 22,599 patients with hypertension and coronary artery disease. *Am J Hypertension*. 2002;15(S3):116A. Poster presentation at the 17th Annual Scientific Meeting of the American Society of Hypertension; May 14 - 18, 2002; New York, NY.
10. **Cooper-DeHoff RM**, Bristol HA, Pepine CJ. Systolic blood pressure control in diabetics and nondiabetics with hypertension and coronary artery disease. *J Am Coll Cardiol*. 2003;41(6 Suppl.):320A. Presentation at the 52nd Annual Scientific Session the American College of Cardiology; March 30–April 2, 2003; Chicago, IL.
11. **Cooper-DeHoff, RM**, Bristol HA, Pepine CJ. Ethnic differences in systolic blood pressure control in hypertensive patients with coronary artery disease. *Am J Hypertension*. 2003; 16(S1):27A. Presentation at the 18th Annual Scientific Meeting of the American Society of Hypertension; May 14-17, 2003; New York, NY.
12. **Cooper-DeHoff, RM**, Gaxiola E, Cangiano JL, Barreto D, Conti, CR, Pepine CJ. Blood pressure reduction and CV outcomes in hypertensive Hispanics, Blacks and Caucasians with coronary artery disease: The International Verapamil Trandolapril Study. *Circulation.* 2003; 108(17 Suppl.): IV-450. Presentation at the 76th Scientific Sessions of the American Heart Association; November 9-12, 2003; Orlando, FL.
13. **Cooper-DeHoff RM**, Bakris G, Cohen J, Messerli F, Erdine S, Bristol H, Pepine CJ. Reduced risk of new onset diabetes in hypertensive coronary artery disease patients treated with a calcium antagonist vs. a beta blocker regimen: the International Verapamil/Trandolapril Study. *Circulation*. 2003; 108(17 Suppl.):IV-750. Presentation at the 76th Scientific Sessions of the American Heart Association; November 9-12, 2003; Orlando, FL.
14. Messerli FH, **Cooper-DeHoff RM,** Kupfer SR, Pepine CJ. Lean Body Mass is Associated with the Highest Incidence of Mortality and Cardiovascular Morbidity in Hypertensive Patients with Coronary Artery Disease: Results from the INternational VErapamil SR/trandolapril STudy (INVEST). Presentation at the 1st World Congress on the Insulin Resistance Syndrome, November 21-22, 2003; Los Angeles, CA.

15. Cohen JD, **Cooper-DeHoff RM**, Bakris GL, Conti R, Pepine CJ. Increased systolic blood pressure is associated with new diabetes in hypertensive patients with coronary artery disease. *Diabetes*. 2004; 53(2):A85. Presentation at the 64th Annual Scientific Session of the American Diabetes Association; June 4-8, 2004; Orlando, FL.
16. **Cooper-DeHoff, RM,** Kolloch R, Messerli FH, Handberg EM, Pepine CJ. Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: the International Verapamil-Trandolapril Study. *J Am Coll Cardiol*. 2004;43(5 Suppl.2):483A. Poster presentation at the 53rd Annual Scientific Session of the American College of Cardiology; March 8, 2004; New Orleans, LA.
17. Mancia G, **Cooper-DeHoff RM**, Hewkin AC, Kupfer SR, Pepine CJ. Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the INternational VErapamil SR-trandolapril STudy. *Am J Hypertension*. 2004;17(S1):116A. Poster presentation at the 19th Annual Scientific Meeting of the American Society of Hypertension; May 18 - 22, 2004; New York, NY.
18. Mancia G, Hewkin A, **Cooper-DeHoff R**, Champion A, Pepine C. Uncontrolled blood pressure is risk equivalent to diabetes and prior myocardial infarction for cardiovascular outcomes: The INternational VErapamil SR-trandolapril STudy. *Eur Heart J*. 2004;25(Suppl.1):662. Presentation at the European Society of Cardiology Congress; September 1, 2004; Munich, Germany.
19. Zineh I, Ma CX, Wessel TR, Arant CB, **Cooper-DeHoff R**, Pauly DF, McGorray SP, Bairey Merz CN, Pepine CJ, Johnson JA. Influence of adrenergic system polymorphisms and nongenetic factors on obstructive coronary artery disease (CAD) in women: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation*. 2004;110(17):III-353. Presentation at the American Heart Association Scientific Sessions; November 7-10, 2004; New Orleans, LA.
20. Pepine CJ, Hewkins A, **Cooper-DeHoff RM**, Champion A, Mancia G. Outcome benefits of BP control in older CAD patients with hypertension: The INternational VErapamil SR-trandolapril STudy (INVEST). *Circulation*. 2004;110(17):III-731. Presentation at the American Heart Association Scientific Sessions; November 7-10, 2004; New Orleans, LA.
21. **Cooper-DeHoff RM**, Aranda JM Jr., Handberg EM, Zhou Q, Pepine CJ. Blood pressure control and cardiovascular outcomes in Hispanic women with coronary artery disease hypertension: Findings from the International Verapamil-Trandolapril Study. *Circulation* 2005;111(4):E76. Poster presentation at the Second International Conference on Women, Heart Disease, and Stroke of the American Heart Association; February 16-19, 2005; Orlando FL.
22. Gong Y, Beitelshees AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Beta 2-adrenergic receptors (B2AR) polymorphism and anti-hypertension response to beta-blocker therapy in the INVEST trial. *Clin Pharmacol Ther*. 2005;77(2):P22. Poster presentation at the 106th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 4, 2005; Orlando, FL.
23. Beitelshees AL, Gong Y, **Cooper-DeHoff RM**, Moss JI, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. *Clin Pharmacol Ther*. 2005; 77(2):P97. Presentation at the 106th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 3, 2005; Orlando, FL.
24. Pepine C, Coca A, Messerli F, Benetos A, Zhou Q, Champion A, **Cooper-DeHoff RM**. Stroke risk in hypertensive patients with coronary artery disease: The INternational VErapamil SR-trandolapril STudy (INVEST). *J Am Coll Cardiol*. 2005;45(3 Suppl.):424A. Presentation at the 54th Annual Scientific Session of the American College of Cardiology; March 8, 2005; Orlando, FL.
25. Elliott W, Hewkin A, Champion A, **Cooper-DeHoff RM**, Pepine CJ. E-prescription database analysis supports use of combination therapy in hypertensive patients with CAD in INVEST. *Am J Hypertension*. 2005;18(S4):58A. Poster presentation at the 20th

Annual Scientific Meeting of the American Society of Hypertension; May 12-18, 2005; San Francisco, CA.

26. **Cooper-DeHoff RM**, Qian Zhou, Pepine CJ. BP control and CV outcomes in Hispanic and Nonhispanic women with CAD and hypertension: Findings from INVEST. *Am J Hypertension*. 2005;18(S4):104A. Poster presentation at the 20th Annual American Society of Hypertension Scientific Meeting; May 12-18, 2005; San Francisco, CA.
27. Messerli F, **Cooper-DeHoff RM**, Champion A, Hewkin A, Pepine CJ. Lean body mass is associated with increased incidence of mortality and cardiovascular morbidity in hypertensive patients with coronary artery disease: The INternational VErapamil-SR-trandolapril STudy (INVEST). *Am J Hypertension*. 2005;18(S4):148A. Presentation at the 20th Annual Scientific Meeting of the American Society of Hypertension; May 12-18, 2005; San Francisco, CA.
28. **Cooper-DeHoff RM**, Gaxiola E, Zhou Q, Handberg EM, Pepine CJ. Verapamil SR-based antihypertensive strategy reduces risk of new onset diabetes in Hispanic patients with coronary artery disease and hypertension: Findings from the INternational VErapamil SR-trandolapril STudy (INVEST). *J Am Diabetes Assoc*. 2005;54(1):1047P. Presentation at the 65th American Diabetes Association Scientific Sessions; June 11th, 2005; San Diego, CA.
29. Mancia G, Zineh I, **Cooper-DeHoff R**, Zhou Q, Champion A, Pepine C. Global Differences in Blood Pressure Control, Findings from The International Verapamil SR-Trandolapril Study (INVEST). *J Hypertens Suppl*. 2005;23(2):S114. Poster presentation at the 15th European Meeting on Hypertension; June 18, 2005; Milan, Italy.
30. Gerhard T, Gong Y, Beitelshees AL, Lobmeyer M, Schiefelbein L, Langaee TY, **Cooper-DeHoff RM**, Johnson JA. Association between CV outcomes, diuretic use and the α-adducin gene: Results from the INternational VErapamil SR-trandolapril STudy (INVEST). *Circulation*. 2005;112(17):II-608. Presentation at the American Heart Association Scientific Sessions; November 15th, 2005; Dallas, TX.
31. Shaw L, Johnson B, **Cooper-DeHoff RM**, Bittner V, Kelsey S, Reis S, Sopko G, Pepine C, Sharaf B, Bairey Merz N. Importance of socioeconomic status as a predictor of cardiovascular outcome in women. *Circulation*. 2005;112(17):II-808. Presentation at the American Heart Association Scientific Sessions; November 15th, 2005; Dallas, TX.
32. **Cooper-DeHoff RM**, Handberg EM, Zhou Q, Champion A, Pepine CJ, and Cohen JD. Larger BMI and Higher Systolic Blood Pressure Are Associated with Increased Risk of Newly Diagnosed Diabetes in Hypertensive Patients With Coronary Artery Disease: Findings from the INternational VErapamil SR-Trandolapril STudy (INVEST). *Circulation.* 2006;113(8):E351. Poster presentation at the 46th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council on Nutrition, Physical Activity, and Metabolism; March 2-5, 2006; Phoenix, AZ.
33. Langaee TY, Yarandi HN, Katz DA, **Cooper-DeHoff RM**, Kehoe JM, Klocman AS, Pepine CJ, Johnson JA. Differences in verapamil response between CYP3A5 genotypes. *Clin Pharmacol Ther*. 2006;79(2):P12. Poster presentation at the 107th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 9, 2006; Baltimore, MD.
34. Brunner M, Karnes JH, Gong Y, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Association of angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with blood pressure response to ace inhibitor in a subgroup of patients of the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther*. 2006;79(2):P14. Poster presentation at the 107th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 9, 2006; Baltimore, MD.
35. Gong Y, Beitelshees AL, Stauffer LA, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Beta adrenergic receptors polymorphisms are associated with response to beta-blocker therapy in the INternal VErapamil SR-Trandolapril Sudy (INVEST). *Clin Pharmacol Ther*. 2006;79(2):P30. Presentation at the 107th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 10, 2006; Baltimore, MD.

36. Beitelshees AL, Gong Y, **Cooper-DeHoff RM**, Burt L, Stauffer LA, Pepine CJ, Johnson JA. KCNMB1 genotype associated with cardiovascular outcomes in the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther*. 2006;79(2):P41. Poster presentation at the 107th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 10, 2006; Baltimore, MD.
37. Johnson JA, Karnes JH, Brunner M, Gong Y, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ. Lack of association of the angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with cardiovascular and cerebrovascular outcomes in a subgroup of patients of the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther*. 2006;79(2):P43. Poster presentation at the 107th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 10, 2006; Baltimore, MD.
38. Handberg E, Gong Y, **Cooper-DeHoff RM**, Ried LD, Pepine CJ. Can an assessment of subjective well being predict outcomes in patients with hypertension and coronary artery disease? A report from the INternational VErapamil-SR/Trandolapril Study. *J Am Coll Cardiol*. 2006;47(4 Suppl.1):300A. Presentation at the 55th Annual Scientific Session of the American College of Cardiology; March 12, 2006; Atlanta GA.
39. Zineh I, Beitelshees AL, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. CXCL5 Gene Polymorphism and Major Cardiovascular Events in The International Verapamil SR-Trandolapril Study (INVEST). *Atherosclerosis Supplements*. 2006;7(3):334. Presentation at the 14thInternational Symposium on Atherosclerosis; June 21, 2006; Rome, Italy.
40. Gerhard T, Gong Y, Beitelshees AL, **Cooper-DeHoff RM**, Johnson JA. Association between CV outcomes, diuretic use and the α-adducin gene: Results from the INternational VErapamil SR-trandolapril STudy (INVEST). *Pharmacoepidemiology and Drug Safety*. 2006;15:S17-S18. Presentation at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2006; Lisbon, Portugal.
41. Gong Y, Handberg EM, Gerhard T, **Cooper-DeHoff RM**, Johnson JA, Pepine CJ. Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the INternational VErapamil SR trandolapril Study (INVEST). *Circulation*. 2006;114(Suppl.18):II_576-II_577. Abstract 2758. Presentation at the American Heart Association Scientific Sessions; November 12-15, 2006; Chicago, IL.
42. **Cooper-DeHoff RM**, McClure CK, Johnson B, Gulati M, Shaw LJ, Handberg EM, Zineh I, Kelsey S, Arnsdorf MF, Black HR, Bairey Merz CN, Pepine CJ. Adverse Cardiovascular Outcomes in Women with No Obstructive Coronary Artery Disease: A Report From The NHLBI-sponsored WISE Study and the St James WTH Project. *Circulation.* 2006;114(Suppl.18):II_399. Abstract 1991. Presentation at the American Heart Association Scientific Sessions; November 12-15, 2006; Chicago, IL.
43. Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, **Cooper-DeHoff RM,** Handberg EM, Berga S, Johnson BD, Bittner V, Rogers W, Pepine CJ, Bairey Merz CN. Cardiovascular Event-Free Survival in Post-Menopausal Women with Polycystic Ovary Syndrome: Results from the Women's Ischemia Syndrome Evaluation. *Circulation*. 2006; 114(Suppl.18): II_902. Abstract 4178. Presentation at the American Heart Association Scientific Sessions; November 12-15, 2006; Chicago, IL.
44. **Cooper-DeHoff RM**, Gerhard T, Gong Y, Handberg EM, Messerli FH, Pepine CJ. Blood Pressure < 120/80 mmHg is Risky in Elderly CAD Patients: Findings from the INternational VErapamil SR Trandolapril STudy (INVEST). *Circulation.* 2007;115(8):e258. P168. Poster presentation at the 47th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council on Nutrition, Physical Activity, and Metabolism; American Heart Association; February 28-March 3, 2007; Orlando, FL.
45. McClure CK, Johnson BD, Gulati M, **Cooper-DeHoff RM**, Shaw LS, Handberg E, Zineh I, Kelsey SF, Armsdorf M, Black H, Bairey CN, Pepine CJ. The Role of the Framingham

Risk Score in Symptomatic Women: A Report from the NHLBI-Sponsored Women's Ischemia Study and the St. James Women Take Heart Project. *Circulation*. 2007;115(8):e253 P146. Poster presentation at the 47th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council on Nutrition, Physical Activity, and Metabolism; February 28-March 3, 2007; Orlando, FL.

46. Pacanowski MA, Gong Y, Langaee TY, **Cooper-DeHoff RM**, Schork NJ, Pepine CJ, Johnson JA. B2-adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the INternational VErapamil SR/trandolapril STudy – GENEtic Substudy (INVEST-GENES). *Clin. Pharmacol. Ther*. 2007;81(S1):S34. Poster Presentation at the 108th American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 22, 2007; Anaheim, CA.
47. Schentrup AM, Nino G, Gong Y, Lima JJ, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. LTA4H variant confers drug therapy –dependant reduced risk of cardiovascular events in INVEST (International Verapamil SR/Trandolapril study). *Clin. Pharmacol Ther*. 2007;81:S35. Poster presentation at the 108th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 22, 2007; Anaheim, CA.
48. Midwall S, Anderson RD, Johnson D, Handberg E, **Cooper-DeHoff R**, Smith K, Pepine C. In Women without Obstructive Coronary Artery Disease, Endothelial-Dependent and Non-Endothelial Dependent Coronary Reactivity Dysfunction are Associated with Different Types of Adverse Outcomes. The NHLBI Women's Ischemia Syndrome Evaluation (WISE). *Circulation*. 2007;116:II_639. Abstract 2870. Presentation at the American Heart Association Scientific Session AOP.45.2: Chronic CAD: Pathophysiology and Prognosis; November 6, 2007; Orlando, FL.
49. Bairey-Merz C, Olson M, McClure C, Symons J, Sopko G, Kelsey S, Handberg-Thurmond E, Johnson BD, **Cooper-DeHoff R**, Sharaf B, Rogers W, Pepine C. A Randomized Controlled Trial of Low Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the NHLBI-sponsored WISE. *Circulation*. 2007;116:II 539. Abstract 2450. Presentation at the American Heart Association Scientific Sessions; ABS Oral Session AOP.45.1: Chronic CAD: New Insights for Medical Therapy and Revascularization; November 6, 2007; Orlando, FL.
50. Denardo SJ, Messerli FH, Gaxiola E, **Cooper-DeHoff RM**, Handberg EM, Champion A, Zhou Q, Pepine CJ. Association of "J-shaped" curves and coronary revascularization status: A substudy of the INVEST. *Circulation*. 2007;116(Suppl. 16):II_842. Abstract 3704. Presentation at the American Heart Association Scientific Sessions; ABS Oral Session AOP.96.4; Coronary Atherosclerosis and Events; November 7, 2007; Orlando, FL.
51. Navare HA, Beitelshees AL, Gong Y, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. CACNA1C Polymorphisms and Cardiovascular Outcomes in the International Verapamil SR/Trandolapril Study – GENEtic Substudy (INVEST-GENES). *Clin Pharm Ther.* 2008; 83(S1):S4. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; Presidential Trainee Awards; April 2, 2008; Orlando, FL.
52. Johnson AD, Gong Y, Wang D, Langaee TY Shin J, **Cooper-DeHoff RM**, Schork NJ, Shriver MA, Binkley PF, Pepine CJ, Johnson JA, Sadee W. Novel Promoter Polymorphisms In Angiotensin-I Converting Enzyme (ACE) Associated With Clinical Outcomes In Hypertensive Coronary Artery Disease (CAD) Patients. *Clinical Pharmacology & Therapeutics*. 2008;83(S1):S8. Presentation at the 2008 Annual ASCPT Meeting; April 2, 2008; Orlando, FL.
53. Pacanowski MA, Zineh I, Welder GJ, Adicks J, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. *NOS3* polymorphisms do not associate with adverse clinical outcomes in elderly hypertensives with cardiovascular disease: Analysis of the INternational VErapamil SR-trandolapril STudy – GENEtic Substudy (INVEST-GENES). *Clin*

Pharmacol Ther. 2008;83(S1):S83. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; April 5, 2008; Orlando, FL.

54. Pacanowski MA, **Cooper-DeHoff RM**, Gong Y, Schork NJ, Pepine CJ, Johnson JA. Diabetes risk associated with β1-adrenergic receptor polymorphisms differs by antihypertensive drug therapy: Results from the INternational VErapamil SR/ trandolapril STudy – GENEtic Substudy (INVEST-GENES). *Clin Pharmacol Ther*. 2008; 83(S1):S83. Poster presentation American Society for Clinical Pharmacology and Therapeutics Annual Meeting; April 5, 2008; Orlando, FL.
55. Price ET, Martin MA, Pacanowski M, **Cooper-DeHoff RM**, Pepine C, Johnson JA, Zineh I. Liver X receptor-α gene variability and cardiovascular risk in the INternational VErapamil SR/Trandolapril STudy – GENEtic Substudy (INVEST-GENES). *Clinical Pharmacology & Therapeutics*. 2008; 83(S1):S66. Poster presentation at the American Society of Clinical Pharmacology and Therapeutics Annual Meeting; April 4, 2008; Orlando, FL.
56. Martin MA, Price ET, Pacanowski M, **Cooper-DeHoff RM**, Pepine C, Johnson JA, Zineh I. *MADD* variants and risk of cardiovascular events in the INternational VErapamil SR/Trandolapril STudy – GENEtic Substudy (INVEST-GENES). *Clinical Pharmacology & Therapeutics*. 2008;83(S1):S82–S83. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; April 5, 2008; Orlando, FL.
57. **Cooper-DeHoff RM**, Pepine CJ. Investigation of the early effects of ACE-I on Glucose Intolerance During Treatment with HCTZ in Patients with Hypertension and Metabolic Syndrome. Presentation at the 15th Annual Consortium for Southeastern Hypertension Control; September 24-27, 2008; Baltimore, MD. Special award Honor.
58. **Cooper-DeHoff RM**, Pepine CJ. Dysglycemia During Treatment with HCTZ in patients with Hypertension and Metabolic Syndrome. *Circulation.* 2008;118(Suppl. 18):S_889. Abstract 4435. Poster presentation at the American Heart Association Scientific Sessions; November 2008; New Orleans, LA.
59. Niu Y, Langaee TY, Gong Y, Moss JI, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. DNA Variations in Voltage-gated Calcium Channel Beta 2 Subunit (CACNB2) Gene, Functional Consequences, and Association with Adverse Cardiovascular Outcomes in the INternational VErapamil SR-trandolapril STudy-GENEtic Substudy. *Circulation*. 2008;118(Suppl. 18):S_885. Abstract 4414. Poster presentation at the American Heart Association Scientific Sessions; November 2008; New Orleans, LA.
60. Denardo SJ, Messerli FH, Aranda JM, **Cooper-DeHoff RM**, Handberg EM, Gong Y, Champion A, Pepine CJ. Association of "J-Shaped" Curves and Age: A Substudy of the International Verapamil SR-Trandolapril Study (INVEST). *Circulation*. 2008;118(Suppl 18):S_1160. Abstract 6216. Presentation at the 2008 American Heart Association Scientific Sessions; November 8-12, 2008; New Orleans, LA.
61. **Cooper-DeHoff RM**, Gong Y, Marin J, Rosen A, Handberg EM, Johnson JA, Pepine CJ. Long-term Mortality Associated with New Onset Diabetes in Hypertensive CAD Patients Following Exposure to Antihypertensive medications: Findings from the INternational VErapamil SR/Trandolapril Study. *J Am Coll Cardiol*. 2009;53(10 Suppl.):A224. Presentation at the 58th Annual American College of Cardiology Meeting; March 30, 2009; Orlando, FL.
62. Welder G, Price E, Duarte J, Handberg EM, Pepine CJ, **Cooper-DeHoff, RM**. PPARγ Downregulation – A Novel Mechanism to Explain HCTZ Associated Dysglycemia in Patients with Hypertension and Metabolic Syndrome. *J Clin Hypertension*. 2009;11:A108. Selected Featured Poster presented at the 24th Annual American Society of Hypertension Scientific Meeting and Exposition; May 7, 2009; San Francisco, CA.
63. Hames ML, Welder GJ, Wittmann J, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA, Beitelshees AL. Aromatase genotype in the INternational VErapamil SR/trandolapril Study (INVEST). *Pharmacotherapy*. 2009; 29:272e. Poster presentation at the 30th

Annual American College of Clinical Pharmacy Meeting; October 19, 2009; Anaheim, CA.

64. Winchester DE, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Incident or Continued Angina During Hypertension Treatment is Associated with Increased Risk of Death, MI or Stroke Among Patients with Known CAD: A Substudy of the International Verapamil SR / Trandolapril Study (INVEST). *Circulation*. 2009;120(Suppl.18):S440-S441. Abstract 1075. Presentation at the American Heart Association Scientific Sessions; November 14-18, 2009; Orlando, FL.
65. Denardo SJ, Wen S, Handberg EM, Bavry AA, Anderson RD, Smith KM, Bairey-Merz CN, Sopko G, **Cooper-DeHoff RM**, Pepine CJ. Effect of Phosphodiesterase Type 5 (PDE-5) Inhibition on Coronary Microvascular Dysfunction in Women: An Ancillary Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). *JACC.* 2010;55(10A): A174.E1630. Presentation at the 59th Annual American College of Cardiology Scientific Sessions; March 16, 2010; Atlanta, GA.
66. Pauly DF, Johnson BD, RD Anderson, Handberg EM, Smith KM, **Cooper-DeHoff RM**, Muller KE, Sopko G, Sharaf BM, Kelsey SF, Bairey Merz CN, Pepine CJ. In Women with Symptoms of Cardiac Ischemia, Nonobstructive Coronary Arteries and Microvascular Dysfunction, Ace Inhibition Is Associated with Improved Microvascular Function: A Double-Blind Randomized Ancillary Study from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). *JACC.* 2010;55(10A):A98.E923. Presentation at the 59th Annual American College of Cardiology Scientific Sessions; March 16, 2010; Atlanta, GA.
67. Davis HM, Allen B, Gong Y, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Clinical Association of Variation in the Beta 2 Regulatory Subunit of the Voltage-Gated Calcium Channel (CACNB2) With Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther*. 2010;87(1):S2&S66. Presentation at the 111th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 17th, 2010; Atlanta, GA. Presidential Trainee Award.
68. Moore MJ, Chik VPW, Gong Y, Langaee T, Chapman AB, Schwartz GL, Turner ST, Gums JG, **Cooper-DeHoff RM**, Beitelshees AL, Johnson JA. Association between melatonin receptor 1B single nucleotide polymorphisms (SNPs) and response to antihypertensive drugs. *Clin Pharmacol Ther*. 2010;87(1):S45. Poster presentation at the 111th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 19th, 2010; Atlanta, GA.
69. Karnes JH, George AM, Gong Y, Langaee TY, Stauffer LA, Burkley BM, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. New onset diabetes risk associated with antihypertensive therapy in hypertensive coronary artery disease patients is modified by a single nucleotide polymorphism in the L-type calcium channel alpha 1c subunit (*CACNA1C*). *Clin Pharmacol Ther*. 2010;87(S1):S45. Poster presented at the 111th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 19th, 2010; Atlanta, GA.
70. Bavry AA, Khaliq A, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Effects of Chronic Nonsteroidal Anti-Inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease - Post-hoc Analysis from the INVEST Trial. *Circulation*. 2010; 122(Suppl. 21):A12424. Poster Presentation at the American Heart Association Scientific Sessions; November 13 - 17 2010; Chicago IL.
71. Gong Y, Beitelshees AL, Lobmeyer MT, Langaee TY, **Cooper-DeHoff RM**, Wu J, Spertus JA, Province MA, Pepine CJ, Johnson JA. Chromosome 9p21 SNPs Haplotypes are Associated with Cardiovascular Outcomes in Patients with Coronary Artery Disease. *Circulation*. 2010;122(Suppl. 21):A16925. Presentation at the American Heart Association Scientific Sessions; November 13 - 17 2010; Chicago IL.
72. Park K, Egelund E, Wen X, **Cooper-DeHoff RM**, Bairey Merz CN, Handberg EM, Johnson BD, Sopko G, Johnson JA, Pepine CJ. Serotonin Transporter Gene Polymorphism in Women with Suspected Ischemia: A Report from the NHLBI-sponsored

WISE. *Circulation*. 2010;122(Suppl. 21): A20055. Poster Presentation at the American Heart Association Scientific Sessions; November 13 - 17 2010; Chicago IL.

73. Davis HM, Gong Y, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. Genetic Variation in the Calcium Signaling Pathway and Association with Outcomes in Hypertensive Coronary Artery Disease Patients. *Clinical Pharmacology & Therapeutics*. 2011;89(S1):S20. Poster presentation at the American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March 3, 2011; Dallas, TX.
74. Karnes H, Vo TT, Gong Y, Langaee TY, Beitelshees AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. KCNJ1 SNPs are Associated with Increased Fasting Glucose and Risk of New Onset Diabetes During HCTZ Therapy. *Clin Pharmacol Ther*. 2011;89(Suppl 1):S46. Poster presentation at the 2011 ASCPT annual meeting; March 4, 2011; Dallas, TX.
75. Vandell AG, Lobmeyer MT, Gawronski B, Langaee TY, Gong Y, Beitelshees AL, Gums JG, Turner ST, Chapman AB, **Cooper-DeHoff RM**, Liggett SB, Johnson JA. Influence of G Protein Kinase 4 (GRK4) Polymorphisms on Blood Pressure Response to the β Blocker Atenolol. *Clin Pharmacol Ther*. 2011; 89(S1):S74. Poster presentation at the American Society of Clinical Pharmacology and Therapeutics Annual Meeting; March 5, 2011; Dallas, TX.
76. Bavry AA, Handberg EM, Wen X, Anderson RD, Smith KM, Lerman A, Quyyumi A, Shufelt C, **Cooper-DeHoff RM**, Sopko G, Pepine CJ. Does Angiotensin Plus Aldosterone Inhibition Improve Coronary Endothelial Function? An Ancillary Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). *JACC*. 2011;57(14):E1047. Poster presentation at the 60th Annual Scientific Session & Expo of the American College of Cardiology; April 4, 2011; New Orleans, LA.
77. Gong Y, McDonough CW, Wang Z, **Cooper-DeHoff RM**, Langaee TY, Beitelshees AL, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA. Hypertension Susceptibility Loci associated with Blood Pressure Response to Antihypertensives - Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *C.lin Pharmacol Ther*. 2012;91(S1):S16. Poster presentation at the 113th Annual American Society of Clinical Pharmacology and Therapeutics Meeting; March 15, 2012; National Harbor, MD.
78. McDonough CW, Burkley B, Gong Y, Langaee TY, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. Non-Synonymous SNPS in *SELE*, *SELP*, and *SIGLEC12* associate with cardiovascular (CV) outcomes in the International Verapamil SR-Trandolapril Study Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther*. 2012;91(S1):S20-S21. Poster presentation at the 113th Annual American Society of Clinical Pharmacology and Therapeutics Meeting; March 15, 2012; National Harbor, MD.
79. Karnes JH, McDonough CW, Gong Y, Langaee TY, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. Alpha adducin-1 (*ADD1*) single nucleotide polymorphism (SNP) associated with new onset diabetes risk with hydrochlorothiazide (HCTZ) therapy in the International Verapamil SR Trandolapril Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther.* 2012;91(S1):S21. Poster presentation at the 113th Annual the American Society of Clinical Pharmacology and Therapeutics Meeting; March 15, 2012; National Harbor, MD.
80. Moore MJ, Gong Y, Hou W, Chapman AB, Langaee TY, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshees AL, **Cooper-DeHoff RM**, Johnson JA. Clinical Predictors of Dysglycemic Effects Associated with Use of Beta Blockers and Thiazide Diuretics. *Clin Pharmacol Ther*. 2012;91(1):S24-25. Poster presentation at the 113th Annual American Society of Clinical Pharmacology and Therapeutics Meeting; March 15, 2012; National Harbor, MD.
81. Moore MJ, Gong Y, Schmidt S, Hall K, Langaee T, Gums JG, **Cooper-DeHoff RM**, Johnson JA. Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose. *Clin Pharmacol Ther.* 2012;91(S1):S25.

Poster presentation at the 113th Annual the American Society of Clinical Pharmacology and Therapeutics Meeting; March 15, 2012; National Harbor, MD.

82. Vandell AG, McDonough CW, Langaee TY, Burkley B, Gong Y, Turner ST, Gums JG, Chapman AB, Beitelshees AL, Bailey KR, Boerwinkle E, **Cooper-DeHoff RM**, Johnson JA. Association of FTO with Hydrochlorothiazide (HCTZ)-Induced Elevation in Uric Acid (UA) in African American (AA) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) Study. *Clin Pharmacol Ther.* 2012;91(S1):S59-S60. Poster presentation at the 113th Annual the American Society of Clinical Pharmacology and Therapeutics Meeting; March 16, 2012; National Harbor, MD.
83. Bavry AA, Gong Y, Kumbhani DJ, Kowey P, Haththotuwa EK, Handberg EM, **Cooper-DeHoff RM**, Pepine, CJ. Simple prediction of long-term mortality among hypertensive patients with coronary artery disease: New data from an extended follow up of the International Verapamil-SR/Trandolapril Study (INVEST). *J Am Coll Cardiol*. 2012;59(13 Suppl.):E1496. Poster presentation at the American College of Cardiology Scientific Sessions; March 26, 2012; Chicago, IL.
84. Winchester DE, Gong Y, **Cooper-DeHoff RM**, Handberg E, Pepine C. Mortality associated with angina and blood pressure control among hypertensive patients with coronary artery disease: new data from extended follow-up of the International Verapamil/Tradolapril Study. *J Am Coll Cardiol*. 2012; 59(13 Suppl.):E1458. Poster presentation at the American College of Cardiology Scientific Sessions; March 26, 2012; Chicago, IL.
85. **Cooper-DeHoff RM**, Gong Y, Handberg E, Messerli F, Bakris G, Ahmed A, Bavry A, Pepine C. Treatment-resistant blood pressure among patients with coronary artery disease—cause for concern: new data from the extended follow-up of the International Verapamil SR-Trandolapril Study (INVEST). *J Am Coll Cardiol*. 2012; 59(13 Suppl.):E1498. Poster presentation at the American College of Cardiology Scientific Sessions; March 26, 2012; Chicago, IL.
86. Khaliq A, Johnson BD, Anderson R, Bavry A, **Cooper-DeHoff RM,** Handberg E, Bairey Merz CN, Pepine C. Relationships between components of metabolic syndrome and coronary intravascular ultrasound (IVUS) atherosclerosis measures in women without obstructive coronary artery disease: The NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. *J Am Coll Cardiol*. 2012;59(13 Suppl.):E1742. Poster presentation at the American College of Cardiology Scientific Sessions; March 25, 2012; Chicago, IL.
87. **Cooper-DeHoff RM**, Shuster J, Lo M, Handberg E, Davoodi-Semiromi A, Pepine CJ. Early effects of ace inhibition on glucose tolerance during thiazide treatment in patients with metabolic syndrome. *J Clin Hypertens*. 2012;14(Suppl.1):A40. Presented at the 27th Annual American Society of Hypertension Meeting; May 19-22, 2012; New York, NY.
88. Bird ST, Munoz M, Winterstein A, **Cooper-DeHoff R**, Delaney JA. Trends in Utilization of Medications with Adverse Metabolic Effects in a Managed Care Population between 1999 and 2008. *Pharmacoepidemiology and Drug Safety*. 2012;21(Suppl 3):300. Presentation at the 28th ICPE meeting; August 23-26, 2012; Barcelona, Spain.
89. Bavry AA, Kumbhani DJ, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Prediction tool for adverse events among patients with hypertension and chronic stable coronary artery disease. *Circulation*. 2012;126:(Suppl 21):A11945. Poster Presentation at the American Heart Association Scientific Sessions; November 5, 2012; Los Angeles, CA.
90. **Cooper-DeHoff RM**, Bird ST, Nichols GA, Delaney JC, Winterstein AG. Association of antihypertensive drug classes, alone or in combination with incident diabetes: a nested case-control study. *Circulation*. 2012; 126(Suppl. 21): A11073. Presentation at the American Heart Association Scientific Sessions; November 5, 2012; Los Angeles, CA.
91. **Cooper-DeHoff RM**, Garvan C, Delaney JA, Winterstein AG, Bavry A, Howard BV, Chen C, Manson J, Phillips LS, Liu S, Song Y, Shorr RI, Limacher M, and Women's

Health Initiative Investigators. Chronic utilization of medications with metabolic effects and risk for incident diabetes in postmenopausal women. *Circulation*. 2012;(Suppl 21)126:A10050. Presentation at the American Heart Association Scientific Sessions; November 5, 2012; Los Angeles, CA.

92. **Cooper-DeHoff RM**, Hou W, Baillie R, Beitelshees AL, Gong Y, Chapman AB, Gums JG, Turner ST, Boyle SH, Zhu H, Wikoff WR, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. *Circulation*. 2012; 126(Suppl 21):A11088. Poster presentation at the American Heart Association Scientific Sessions; November 4, 2012; Los Angeles, CA.
93. Gong Y, Moore MJ, Karnes JH, McDonough CW, Wang Z, Langaee TY, Beitelshees AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Johnson JA, **Cooper-DeHoff RM**. Fasting Glucose Loci Associated with Glucose Response to Antihypertensives-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). *Clin Pharmacol Ther*. 2013;93(S1):S28. Presentation at the 114th Annual American Society for Clinical Pharmacology and Therapeutics meeting; March 20, 2013; Indianapolis, IN.
94. Bird ST, Delaney JA, **Cooper-DeHoff RM**, Nichols GA, Winterstein AG. Misclassification in Assessment of Diabetogenic Risk Using Laboratory-Enhanced Claims Data. *Pharmacoepidemiology and Drug Safety*. 2013;22(Suppl1):3–4. Presentation at the 29th ICPE meeting; August 26, 2013; Montreal, Canada.
95. Gong Y, McDonough CW, Wang Z, Langaee TY, Beitelshees AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses Study. *Clin Pharmacol Ther* 2014;95(S1):S16-S17. Presentation at the 115th Annual American Society for Clinical Pharmacology and Therapeutics Annual meeting; March 20, 2014; Atlanta, GA.
96. Chang S, McDonough CW, Gong Y, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. A Pharmacogenomic Genome-wide Association Study (GWAS) for New onset diabetes in the International Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther*. 2014;95(S1):S59-S60. Presentation at the 115th Annual American Society for Clinical Pharmacology and Therapeutics Annual meeting; March 20, 2014; Atlanta, GA.
97. Fontana V, McDonough CW, Gong Y, El Rouby NM, Sá AC, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. ATP2B1 Locus is Associated with Resistant Hypertension in the International Verapamil SR-Trandolapril Study-Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther*. 2014;95(S1):S26-S27. Poster presentation at the 115th Annual American Society for Clinical Pharmacology and Therapeutics Annual meeting; March 20, 2014; Atlanta, GA.
98. McDonough CW, Gong Y, Langaee TY, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. A Pharmacogenomic Genome-Wide Association Study for Adverse Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther.* 2014;95(S1):S71. Poster presentation at the 115th Annual American Society for Clinical Pharmacology and Therapeutics Annual meeting; March 21, 2014; Atlanta, GA.
99. Bavry AA, Gong Y, Handberg E, **Cooper-DeHoff R**, Pepine C. Is Aspirin Beneficial for all Patients with Chronic Stable Coronary Artery Disease? *JACC*. 2014;63(12):A1564. Poster presentation at the 63rd Annual Scientific Session & Expo of the American College of Cardiology; March 29, 2014; Washington, DC.
100. Vilaro JR, Huo T, **Cooper-DeHoff RM**, Handberg E, Sopko G, Kelsey S, Bairey Merz N, Pepine CJ. Brachial Pulse Pressure Predicts Adverse Outcomes Including Heart Failure Hospitalizations in Women With Preserved Ejection Fraction and No Obstructive Coronary Artery Disease: *A Report from the Women's Ischemia Syndrome Evaluation*. *Circulation*. 2014;130:A11580. Poster presentation at the 63rd Annual

Scientific Session & Expo of the American College of Cardiology. March 29-31, 2014; Washington, DC.

101. Sa AC, Webb A, Gong Y, Langaee T, Turner S, Chapman A, Gums J, Scherer S, **Cooper-DeHoff RM**, Sadee W, Johnson JA. Identifying Differentially Expressed Genes Associated with Extreme Blood Pressure Response to Hydrochlorothiazide monotherapy. Abstract 732M. Poster presentation at the 64th Annual Meeting of The American Society of Human Genetics; October 20, 2014; San Diego, CA
102. El Rouby N, McDonough CW, Gong Y, Pepine CJ, Takahashi A, Tanaka T, Kubo M, **Cooper-DeHoff RM**, Johnson JA. Genome-wide association study of resistant hypertension in INVEST. Abstract 702M. Poster presentation at the 64th Annual Meeting of The American Society of Human Genetics; October 20, 2014; San Diego, CA.
103. Winterstein AG, **Cooper-DeHoff RM**, Kubilis P, Nichols G, Delaney JAC. Diabetogenic effects of atypical antipsychotics – exploration of measurement bias. *Pharmacoepi Drug Saf.* 2014;23(S1):142-143. Presentation at the 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management; October 24-27, 2014; Taipei, Taiwan. Spotlight poster winner – Methods Special Interest Group.
104. Smith SM, Huo T, Gong Y, Handberg EM, Gulati M, Bairey Merz CN, Pepine C, **Cooper-DeHoff RM**. Mortality Risk Associated with Apparent Treatment-Resistant Hypertension Among Women. *Circulation*. 2014;130:A17677. Presentation at the American Heart Association Scientific Sessions; November 16, 2014; Chicago, IL.
105. Biel N, Lim C, Santostefano K, **Cooper-DeHoff R**, Johnson J, Terada N. Generation of vascular cells from patient derived iPSC to model hypertension. *The FASEB Journal*. 2014;28(Suppl 1): LB537. Presentation at the 2014 FASEB SRC.
106. Chang S, Gong Y, McDonough CW, Nasiri-Kenari N, Langaee T, Beitelshees AL, Gums JG, Chapman AB, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Correlating the Melatonin (MT) Pathway with Atenolol Associated Glucose Dysregulation in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Clin. Pharmacol. Ther*. 2015;97(Suppl 1):S17. Presentation at the 116th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 4th, 2015; New Orleans, LA. Presidential Trainee Awards.
107. Shahin MH, Gong Y, Langaee T, Beitelshees AL, Rotroff DM, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Fiehn O, Johnson JA, **Cooper-DeHoff RM**, Han X, Kaddurah-Daouk R. Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Clin. Pharmacol. Ther.* 2015;97:S30. Poster presentation at the 116th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 3rd, 2015, New Orleans, LA.
108. Shahin MH, Rotroff DM, Gong Y, Langaee T, McDonough CW, Beitelshees AL, Garrett TJ, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Scherer SE, Sadee W, Fiehn O, **Cooper-DeHoff RM**, Kaddurah-Daouk R, Johnson JA. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (PEAR) Study. *Clinical Pharmacology & Therapeutics*. 2015;97:S11. Presented at the 116th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 3, 2015; New Orleans, LA. Presidential Trainee Award.
109. **Cooper-DeHoff RM**, Weng L, Culver J, Gardell SJ, Petucci CJ, Morse AM, Frye RF, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett, TJ, McIntyre LM. Pharmacometabolomics Identifies Acylcarnitines Associated with Beta blocker Induced Fasting Glucose Altertations. Poster 148. Poster presentation at the 11th Annual International Conference of the Metabolomics Society; June 29, 2015; San Francisco, CA. Selected by NIH for travel award.
110. Solayman MH, Langaee T, Gong Y, El-Hamamsy M, El-Wakeel L, Boerwinkle E, Chapman A, Turner S, Gums J, Beitelshees A, **Cooper-DeHoff RM**, Badary O, Johnson JA. Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers.

Clinical Pharmacology in Drug Development. 2015;4(S1):58-59. Presentation at the 44th Annual American College of Clinical Pharmacology Meeting; September 28, 2015; San Francisco, CA. Student Award Winner.

111. Shahin MH, Sa AC, Webb A, Gong Y, Langaee T, McDonough CW, Beitelshees AL, Chapman AB, Gums JG, Turner ST, Frye RF, Scherer SE, Sadee W, **Cooper-DeHoff RM**, Johnson JA. Identifying a Novel Hypertension Genetic Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Abstract #674. Poster presentation at the 65th Annual Meeting of the American Society of Human Genetics; October 7, 2015; Baltimore, MD.
112. Sa AC, Webb A, Gong Y, McDonough CW, Langaee T, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer S, **Cooper-DeHoff RM**, Sadee W, Johnson JA. Molecular Markers of Blood Pressure Response to Thiazide Diuretics Identified Through Whole Transcriptome RNA-Seq Analysis. Abstract #656. Poster presentation at the 65th Annual Meeting of the American Society of Human Genetics; October 7, 2015; Baltimore, MD.
113. El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Takahashi A, Tanaka T, Kubo M, Pepine CJ, **Cooper-DeHoff RM**, Benavente OR, Shuldiner AR, Johnson JA. Novel genetic loci for resistant hypertension discovered through a genome-wide association approach (GWAS) in the INternational VErapamil SR-Trandolapril STudy (INVEST) and the Secondary Prevention of Subcortical Strokes (SPS3) Study. Abstract # 665. Poster presentation at the 65th Annual Meeting of the American Society of Human Genetics: October 8, 2015; Baltimore, MD.
114. Weitzel K, Cavallari LH, Elsey A, Owusu-Obeng A, Staley B, Ashton J, Vo T, Kong B, Higgins T, **Cooper-DeHoff R**, Johnson J. Development and implementation of pharmacist-led clinical pharmacogenetics services within a personalized medicine program. *Pharmacotherapy*. 2015;35(11):e225. Poster presentation at the 2015 ACCP Global Conference on Clinical Pharmacy; October 17-21, 2015; San Francisco, CA.
115. Cavallari LH, Magvanjav O, Anderson RD, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Elsey AR, **Cooper-Dehoff RM**, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Fewer cardiovascular events after percutaneous coronary intervention with genotype-guided antiplatelet therapy: results from the UF Health Personalized Medicine Program. *Pharmacotherapy*. 2015;35(11):e207. Poster presentation at the 2015 ACCP Global Conference on Clinical Pharmacy; October 17-21, 2015; San Francisco, CA.
116. El Rouby N, McDonough CW, Gong Y, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Takahashi A, Tanaka T, Kubo M, Pepine C, **Cooper-DeHoff RM**, Benavente O, Shuldiner AR, Johnson JA. Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). *Circulation*. 2015;132:A15465. Poster presentation at the 2015 AHA Scientific Sessions; November 8, 2015; Orlando, FL.
117. Shahin MH, Rotroff DM, Webb A, Gong Y, Langaee T, McDonough CW, Beitelshees AL, Garrett T, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Scherer SE, Sadee W, Fiehn O, **Cooper-DeHoff RM**, Kaddurah-Daouk R, Johnson JA. Integrating Metabolomics and Genomics Uncovers Novel Pathways and Genetic Signatures Influencing Hydrochlorothiazide Blood Pressure Response: A Genetic Response Score for Hydrochlorothiazide Use. *Circulation*. 2015;132:A13621. Poster presentation at the 2015 AHA Scientific Sessions; November 8, 2015; Orlando, FL.
118. Cavallari LH, Magvanjav O, Anderson RD, Gong Y, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Elsey AR, Allan RW, Starostik P, **Cooper-DeHoff RM**, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical Implementation Of CYP2C19-genotype Guided Antiplatelet Therapy Reduces Cardiovascular Events After PCI. *Circulation*. 2015;132:A11802. Poster presentation at the 2015 AHA Scientific Sessions; November 9, 2015; Orlando, FL.

119. de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, **Cooper-DeHoff RM**. Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers In DPYS Associated With Higher Glucose Change After Treatment With Atenolol. *Circulation*. 2015;132:A18338. Poster presentation at the 2015 AHA Scientific Sessions; November 10, 2015; Orlando, FL.
120. Sa AC, Webb A, Gong Y, McDonough CW, Shahin MH, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer S, **Cooper-DeHoff RM**, Sadee W, Johnson J A. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. Clinical *Pharmacology & Therapeutics*. 2016; 99:S19 (PT23). Poster Presentation at the 117th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 9, 2016; San Diego CA. Presidential Trainee Award.
121. Shahin MH, Sa AC, Webb A, Gong Y, Langaee T, McDonough CW, Riva A, Beitelshees AL, Chapman AB, Gums JG, Turner ST, Frye RF, Scherer SE, Sadee W, **Cooper-DeHoff RM**, Johnson JA. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics*. 2016;99:S19 (PT24). Poster presentation at the 117th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 9, 2016; San Diego CA. Presidential Trainee Award.
122. Elgendy I, Bavry A, Gong Y, Handberg E, **Cooper-DeHoff R**, Pepine C. Long-term mortality in a cohort of hypertensive patients with coronary artery disease: results from an extended follow up of the International Verapamil/ Trandolapril Study (INVEST) project. *JACC*. 2016;67(13):2015. Poster presentation at the 65th Annual Scientific Session & Expo of the American College of Cardiology, ACC.16; April 04, 2016; Chicago, IL.
123. Bargal S, Kight J, de Oliveira F, Shahin M, Langaee T, Gong Y, Hamadeh I, **Cooper-DeHoff R**, Cavallari L. Implications of polymorphisms in BCKDK and GATA-4 genetic regions on stable warfarin dose in African Americans. *Pharmacotherapy*. 2016;36(12):e267. Abstract #250. Poster presentation at the ACCP Annual Meeting; October 23, 2016; Hollywood, FL.
124. Mehanna M, Gong Y, McDonough CW, Beitelshees A, Gums J, Chapman AB, Johnson J, Turner S, **Cooper-DeHoff R**. The role of plasma renin activity for improving precision of antihypertensive drug therapy in European Americans and African Americans. *Pharmacotherapy*. 2016;36(12):e214. Abstract #40. Poster presentation at the ACCP Annual Meeting; October 24, 2016; Hollywood, FL.
125. Shahin M, Conrado D, Gonzalez D, Gong Y, Lobmeyer M, Beitelshees A, **Cooper-DeHoff R**, Boerwinkle E, Turner S, Chapman A, Gums J, Johnson J. Identifying novel genetic predictors associated with heart rate response to beta-blockers. *Pharmacotherapy*. 2016;36(12):e265-266. #244. Poster presentation at the 2016 ACCP Annual Meeting; October 24, 2016; Hollywood FL.
126. Cavallari LH, Denny JC, Lee CR, Beitelshees AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, **Cooper-DeHoff RM**, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. *Circulation*. 2016;134(25):e711-712. Abstract #21050. Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association's Scientific Sessions; November 15, 2016; New Orleans, LA.
127. Singh S, Alghamdi W, Arwood MJ, Bargal SA, de Oliveira F, Dumeny L, Wen-Yi L, Mehanna M, Stockard B, Yang G, Fredette N, Shahin M, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Gong Y, McDonough CW, **Cooper-DeHoff RM**, Johnson JA. A Genome Wide Association Study Identifies

Pharmacogenomic Variants Associated with Chlorthalidone Induced Glucose Change in African Americans. *Clinical Pharmacology & Therapeutics*. 2017;101(S1):S9 (PT-019). Poster presentation at the 118th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 15, 2017; Washington, DC. Presidential Trainee Award.

128. Shahin MH, Michailidis G, Gong Y, Beitelshees AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Thiazide Induced Hyperuricemia: Novel Insights from Metabolomics and Genomics Integration in the Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR 2) Study. *Clinical Pharmacology & Therapeutics*. 2017; 101(S1): S13 (PT-028). Presentation at the 118th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 15-16, 2017; Washington, DC. Presidential trainee award.
129. El Rouby N, McDonough CW, Gong Y, Mcclure LA, Mitchell BD, Horenstein RB, Talbert RL, Bradford Y, Crawford DC, Ritchie MD, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Benavente OR, **Cooper-DeHoff RM**, Johnson JA. A GWAS of Resistant Hypertension in the INternational VErapamil SR-trandolapril Study (INVEST) and Secondary Prevention of Small Subcortical Strokes (SPS3). *Clinical Pharmacology & Therapeutics*. 2017;101:S27-S28. (PI 029). Poster presentation at 118th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 16, 2017; Washington, DC.
130. Solayman MH, Langaee TY, Gong Y, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshees AL, El-Wakeel L, El-Hamamsy M, **Cooper-DeHoff RM**, Badary OA, Johnson, JA. Association of ADRB1 Gene DNA Methylation with Antihypertensive Response to Metoprolol in the Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR-2) Study. *Clinical Pharmacology & Therapeutics*. 2017;101(S1):S47 (PI-106). Poster presentation at the 118th Annual American Society for Clinical Pharmacology and Therapeutics Meeting; March 16, 2017; Washington, DC.
131. Costa Sa A, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, **Cooper-DeHoff RM**, Sadee W, Johnson JA. RNA-Seq Analyses Identify Molecular Markers of Blood Pressure (BP) Response to Thiazide Diuretics (TD). *Clinical Pharmacology & Therapeutics*. 2017;101(S1):S12,S95 (PT-025,PWIV-001). Poster presentation at the 118th Annual American Society for Clinical Pharmacology & Therapeutics Meeting; March 17, 2017; Washington, DC. Presidential Trainee Award.
132. Gong Y, Nguyen HK, Szady A, Hamadeh I, Lipori G, Sun Q, **Cooper-DeHoff RM**, Langaee TY, Shah C, Pepine CJ, Lucas AR, Moreb J. Cardiomyopathy Associated with Targeted Anticancer Therapies in Electronic Health Records. *J Am Coll Cardiol.* 2017; 69(11 Suppl): 925. Poster presentation at the 66th Annual Scientific Sessions of the American College of Cardiology; March 19, 2017; Washington, DC.
133. Wokhlu A, Gong Y, **Cooper-DeHoff R**, Smith SM, Handberg E, Pepine C. Relationship Between Diastolic Blood Pressure and All-Cause Mortality with Lower Systolic Blood Pressure Among Hypertensive Patients with Coronary Artery Disease: Long-Term Follow-Up of The US Cohort of The International Verapamil Sr-Trandolapril Study (INVEST). *JACC.* 2017;69(11 Suppl):1685. Poster presentation at the 66th Annual Scientific Session & Expo; March 19, 2017; Washington, DC.
134. McDonough CW, Hogan WR, Shenkman EA, **Cooper-DeHoff RM**. Characterization of Resistant Hypertension in a Statewide Electronic Health Record-Based Database (OneFlorida). *Journal of Clinical and Translational Science*. 2017;1(S1):13. Poster presentation at the Association for Clinical and Translational Science (ACTS) – Translational Science Meeting; April 20, 2017; Washington, DC.
135. Bejjanki H, Gong Y, Willis D, Siler-Marsiglio K, Handberg E, Haight D, Smith S, Pepine C, **Cooper-DeHoff R**. Perception of Blood Pressure Control and Satisfaction with Hypertension Care in the Rural Setting. *Hypertension*. 2017;70:AP220. Trainee Onsite Poster Competition. Poster presentation at the 2017 American Heart Association's Joint Hypertension Scientific Sessions; September, 14, 2017; San Francisco, CA.

136. Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. Towards precision therapy in hypertension: Genome-wide association study reveals genetic variants associated with uncontrolled blood pressure on thiazide diuretic/beta-blocker combination therapy. Abstract 2713W. Presentation at the 67th Annual Meeting of the American Society of Human Genetics; Orlando, FL; October 18, 2017.
137. Shahin MH, Akoluk A, Singh S, McDonough CW, Gong Y, Chapman AB, Turner ST, Gums JG, Beitelshees AL, Boerwinkle E, **Cooper-DeHoff RM**, Johnson JA. A genome-wide association study identifies novel genetic signatures associated with thiazide diuretics adverse metabolic events. Abstract 2678T. Poster presentation at the 67th Annual Meeting of The American Society of Human Genetics; Orlando, FL; October 19, 2017.
138. Singh S, Gong Y, McDonough CW, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome-wide association study reveals novel genetic markers associated with chlorthalidone blood pressure response. Abstract 2685F. Poster presentation at the 67th Annual Meeting of The American Society of Human Genetics; Orlando, FL; October 20, 2017.
139. Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, McDonough CW, Bailey KR, Turner ST, Chapman A, Gums JG, Beitelshees AL, **Cooper-DeHoff RM**, Scherer S, Boerwinkle E, Johnson JA. Targeted Sequencing Identifies Missense Variant in the *BEST3* Gene Associated with Antihypertensive Response to Thiazide Diuretics. *Clinical Pharmacology & Therapeutics*. 2018;103:S5. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 21, 2018; Orlando, FL. Goldstein Trainee Award.
140. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome-Wide Meta-Analyses Reveal Novel Predictors of Heart Rate Response to β-Blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Studies. *Clinical Pharmacology & Therapeutics*. 2018;103:S15. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 22, 2018; Orlando, FL.
141. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, **Cooper-DeHoff RM**, Johnson JA. β2-Adrenergic Receptor Gene Affects the Negative Chronotropic Effects of β-Blockers in the PEAR and PEAR 2 Studies. *Clinical Pharmacology & Therapeutics*. 2018;103:S15-S16. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 22, 2018; Orlando, FL.
142. Magvanjav O, McDonough CW, Gong Y, **Cooper-DeHoff RM**, Hogan WR, Johnson JA. Combination antihypertensive therapy prescribing among outpatients: Evidence from an electronic health records database. *Clinical Pharmacology & Therapeutics*. 2018;103:S43. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 22, 2018; Orlando, FL.
143. Singh S, Gong Y, McDonough CW, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome Wide Association Study Identifies Novel Pharmacogenetic Variants Associated with Chlorthalidone Blood Pressure Response in African Americans. *Clinical Pharmacology & Therapeutics.* 2018;103:S50. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 22, 2018; Orlando, FL.
144. Campbell D, Aman A, Iniesta R, Menni C, Gong Y, **Cooper-DeHoff RM**, Johnson J, Burgess K, Barrett M, Lewis C, Chowienczyk P, Padmanabhan S, PEAR Investigators. Pharmaco-Metabolomics of Blood Pressure Response to Beta-Blockers And Diuretics.

Hypertens J. 2018;36:e124-e125. Presentation at the ESH 28th European Meeting on Hypertension and Cardiovascular Protection; June 10, 2018; Barcelona, Spain.

145. Shahin MH, Kovar LG, Smith DM, Elsey AR, Weitzel KW, Anderson RD, **Cooper-DeHoff RM**, Nelson DR, Johnson JA, Cavallari LH. Impact of Different P2Y12 Inhibitors on Cardiovascular Outcomes in Diabetic versus Non-Diabetic Patients: Insights From Real-World Data. *Circulation*. 2018;138(Suppl_1):A12787. Poster presentation at the American Heart Association Scientific Sessions; November 11, 2018; Chicago, IL.
146. Lemas DJ, Cardel M, Filipp SL, Hall J, Essner RZ, Smith SR, Nadglowski J, Donahoo WT, **Cooper-DeHoff RM**, Nelson DR, Hogan WR, Shenkman EA, Gurka MJ, Janicke DM. Objectively Measured Pediatric Obesity Prevalence Using the OneFlorida Clinical Research Consortium. Poster presented at The Obesity Society Annual Scientific Meeting, Obesity Week; November 14, 2018; Nashville, TN.
147. Chekka LMS, Singh S, Langaee TY, Chapman AB, Gums JG, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Systematic, Hypothesis-Driven Approach to Identify Circulating MicroRNAs That Predict Blood Pressure Response to Antihypertensive Drugs. *Clinical Pharmacology & Therapeutics.* 2019;105(S1):S89 (PIII-024; PGRN-011). Poster presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 15, 2019; Washington, DC.
148. Mehanna M, Chen YE, Gong Y, Handberg E, Roth B, De Leon J, Smith SM, Harrell JG, **Cooper-DeHoff RM**. Optimizing Precision of Hyperension Care to Maximize Blood Pressure Control (OPTI-BP): A Pilot Study Utilizing a Smartphone App. 4 Sep 2019 https://doi.org/10.1161/hyp.74.suppl_1.P181 Hypertension. 2019;74:AP181
149. Villanueva M, Chen YE, Smith SM, Gong Y, Handberg EM, Pepine CJ, Keeley EC, **Cooper-DeHoff RM**. Attended Versus Unattended Blood Pressure Measurement in Patinets with Cardiovascular Disease: Does it Matter? 4 Sep 2019 https://doi.org/10.1161/hyp.74.suppl_1.026 Hypertension. 2019;74:A026
150. **Cooper-DeHoff RM**, Holmes HR, Li Q, Xu K, Seungbum K, Richards EM, Keeley EC, Handberg EM, Smith SM, Raizada MK, Pepine CJ. A Pilot Study of Antihypertensive Medication Adherence Trends by Sex and Drug Class. 4 Sep 2019 https://doi.org/10.1161/hyp.74.suppl_1.032 Hypertension. 2019;74:A032
151. Pletcher MJ, Fontil V, Carton T, Shaw K, Smith M, Todd J, Chamberlain AM, Obrien E, Faulkner M, Maeztu C, Wozniak G, Rakotz M, Shay C, Cooper-DeHoff RM. The PCORnet Blood Pressure Control Laboratory. 4 Sep 2019 https://doi.org/10.1161/hyp.74.suppl_1.P2050 Hypertension. 2019;74:AP2050
152. Cicali EJ, Cook KJ, Arwood MJ, Staley B, Thomas CD, Dalton R, Elsey A, Cavallari LH, Johnson JA, **Cooper-DeHoff RM**, Wiisanen K. Development of Standardized Clinical Resources to Support Implementation of a Preemptive Pharmacogenomics Testing Panel. *Clin Pharmacol Ther*. 2020;107: S57. (PII-079)
153. **Cooper-DeHoff RM**, Fontil V, Carton T, Shaw KM, Smith M, Choi S, Todd J, Chamberlain AM, O'Brien EC, Faulkner M, Maeztu C, Wozniak G, Rakotz M, Shay CM, Pletcher MJ. Blood Pressure Control Suveillance In The Real World – Early Evidence from A National Blood Pressure Surveillance System. Oral Abstract Presentation 2 Mar 2020 https://doi.org/10.1161/circ.141.suppl_1.56 Circulation. 2020;141:A56
154. Yang G, Chen Y, Tantawy M, Pruitt E, Pepine CJ, **Cooper-DeHoff RM**, Qing Lu, Gong Y. *ACE2* Polymorphisms and COVID-19: An analysis from the UK Biobank. *Clin Pharmacol Ther.* 2021. Abstract to be presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting (Presidential Trainee Award).
155. Tantawy M, Yang G, Chen Y, Pruitt E, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Qing Lu, Gong Y. Genome-wide Association study of Mortality in COVID-19 Patients in The UK Biobank Data. *Clin Pharmacol Ther.* 2021. Abstract to be presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting.

156. Chen Y, Yang G, Singh S, Langaee TY, **Cooper-DeHoff RM**, Tantawy M, Pruitt EY, Pepine CJ, Lu Q, Gong Y. Three Lipid-related Loci Potentially Associated with SARS-Cov-2 infection in the UK Biobank Participants. Presented as a late-breaking poster at the 70th Virtual Meeting of the American Society of Human Genetics (ASHG), October 27-30, 2020.

157. Yang G, Chen Y, Tantawy M, Pruitt E, Pepine CJ, **Cooper-DeHoff RM**, Qing Lu, Gong Y. *ACE2* Polymorphisms and COVID-19: An analysis from the UK Biobank. *Clin Pharmacol Ther*. 2021 (109): S27: PT21-015. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting (Presidential Trainee Award).

158. Mehanna M, Gong Y, McDonough CW, Gums JG, Chapman AB, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Metabolomics Reveals Racial Difference in Blood Pressure Response to Metoprolol. American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics 2021; S5:S88. . Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting (Presidential Trainee Award) (PT21-002)

159. McDonough CW, **Cooper-DeHoff RM**, Hogan WR. Characterizing Resistant Hypertension (RHTN) and Antihypertensive Medication Usage in RHTN Patients within the State of Florida Using Electronic Health Record (EHR)-Based Data. Clinical Pharmacology & Therapeutics 2021, 109 (S1):S77-S78: PIV-054. Abstract accepted for poster presentation at the American Society for Clinical Pharmacology and Therapeutics 2021 Virtual Annual Meeting.

160. Mehanna M, Gong Y, McDonough CW, Gums JG, Chapman AB, Johnson JA, McIntyre L, **Cooper-DeHoff RM**. Metabolomic Differences Associated with Genetic West African Ancestry Among Hypertensive Patients. American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics 2022 (selected for a Top Poster Ribbon). (ASCPT 2022 Annual Meeting)

161. Thomas CD, Yang G, Elbalkiny S, Huang Y, Nahid N, Nguyen N, Mehanna M, Boerwinkle E, Chapman AB, Gums JG, Gong Y, Johnson JA, **Cooper-DeHoff RM**, McDonough CW. Genetic Association of Uric Acid Change After Thiazide/Thiazide-like Diuretic Treatment – Analysis of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Studies. American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics 2022. (ASCPT 2022 Annual Meeting)

PATENTS

US Patent No. 5,991,731
Title: Method and System for Interactive Prescription and Distribution of Prescriptions in Conducting Clinical Studies
UF Reference Number: 1682

INVITED JOURNAL REFEREE:

1. Psychosomatic Medicine
2. Pharmacotherapy
3. Journal of Human Hypertension
4. Clinical Cardiology
5. Circulation
6. Long Term Care Interface
7. British Journal of Clinical Pharmacology
8. Pharmacogenomics

9. Expert Review of Cardiovascular Therapy
10. Pharmacogenetics and Genomics
11. Lancet
12. Archives of Internal Medicine
13. JAMA
14. Journal of Women's Health
15. Nature Communications
16. Journal of Clinical Hypertension
17. Circulation – Quality and Outcomes
18. Pharmacogentics and Genomics
19. Circulation Research
20. American Journal of Medicine
21. American Journal of Health System Pharmacists
22. American Heart Journal Plus

EDITORIAL ACTIVITIES:

Editorial Board 2021-Present	American Heart Journal Plus
Managing Editor 2022	American Heart Journal Plus Special Issue on Deprescribing
Editor – 2016-Present	Pharmacology Column American Journal of Medicine
Editorial Board – 2005-2015	Cardiology Today Cardiovascular Pharmacology Section

Invited Quarterly Column – Cardiology Today, Pharmacology Consult
2005-2015

November 2006	FDA: Separate Ibuprofen and Aspirin
February 2007	Grapefruit – Drug Interaction: Important Considerations for Heart Disease Patients
May 2007	With OTC Simvastatin, U.K.'s Statin Prescriptions Down
August 2007	Taking Steps to Reduce NSAID Risks
November 2007	Patients Beware: Ways to minimize medication errors
February 2008	Genotype-guided warfarin dosing now a reality. An NIH study planned for this year will assess multiple outcomes related to warfarin safety and efficacy.
May 2008	Despite efforts, limited efficacy exists for dietary supplements, p.16
August 2008	Low-cost generic programs help make medication co-pays more affordable.

SELECTED INVITED PRESENTATIONS

1. Justifying, Implementing, and Financing Investigational Drug Services at Shands Hospital. Presented at the ASHP Midyear Meeting; December 1990; Las Vegas, NV.
2. Computerization of an Investigational Drug Service Data Base. Presented at: University Hospital Consortium's Technology Advancement Center Meeting; March 1991; Chicago, IL.

3. Formulary Management of Biotechnology Through a Subcommittee. Presented at: Biotechnology Institute, Charlotte; September 1993, August 1994; NC.
4. Justifying, Implementing and Financing an Investigational Drug Service - an Update. Presented at: FSHP annual meeting; August 19, 1994; Orlando, FL.
5. Participant in “Today in Cardiology” Roundtable. The Safety of Cox-2 Inhibitors in Patients with CHD; February 2001; Anaheim, CA.
6. Managing Hypertension in CAD Patients: What Have the Clinical Trials Taught Us? Are the JNC VI guidelines being followed in the 21st Century? Presented at: American College of Cardiology, Twenty-first annual perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology; January 27, 2002.
7. Managing Hypertension in Patients with CAD. Presented at: Florida Society of Health System Pharmacists annual meeting; November 10, 2022; Jacksonville, FL.
8. Hypertension: New Observations on Gender, Ethnicity, and Diabetes from INVEST. Presented at: American College of Cardiology, Twenty-second annual perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology; January 24, 2003.
9. Managing Blood Pressure and Cardiovascular Risk in the Complex Patient – a Focus on the Guidelines and the Evidence. Presented at: North Central Florida Society of Health System Pharmacists; March 31, 2004.
10. Pharmacologic Management of Hypertension. Presented at: American College of Cardiology; March 11, 2006; Atlanta, GA.
11. Women’s Heart Health: An Update. Shands Women’s Advantage; February 15, 2007
12. CAD, Inflammation and COX-2 Inhibitors. Presented at: North Central Florida Society of Health System Pharmacists; March 14, 2007.
13. Women’s Heart Disease – New Prevention Guidelines. Presented at: Prime Time Institute; May 31, 2007; Gainesville, FL.
14. Facilitating Investigator Initiated Research within the Cardiovascular Medicine Division, Cardiovascular Grand Rounds; August 23, 2007; Gainesville, FL.
15. Cardiovascular Medications – an update. Presented at: Oak Hammock Community; October 2, 2007; Gainesville, FL.
16. Hypertension: Evidence Based Treatments to Improve Patient Outcomes. Presented at: American Health Resources, CVS Pharmacists; October 14 and 29, 2007; Ocala and Tampa, FL.
17. Supplements: Where’s the Evidence? Presented at: American College of Cardiology Annual Scientific Sessions; March 2008; Chicago, IL.
18. Investigation of the early effects of ACE-I on Glucose Tolerance During Treatment with HCTZ in Patients with Hypertension and Metabolic Syndrome. Presented at: Center for Pharmacogenomics Seminar; October 2008.
19. Antidepressant medications in the cardiovascular patient. American College of Cardiology Annual Scientific Sessions, Pharmacology Program; March 2009; Orlando, FL.
20. Programs for getting and keeping your patients on their medications. American College of Cardiology Annual Scientific Sessions; March 29, 2009; Orlando, FL.
21. Brown Bag Supplements: Where’s the Evidence? Preventive Cardiovascular Nurses Association Annual Meeting; April 2009; Dallas, TX.
22. Herbals and Other Alternative Therapies: Just What Is Your Patient Taking? Presented at: Cardiovascular Grand Rounds, January 14, 2010; Gainesville, FL.
23. Rethinking Lower BP Goals for Diabetics with Documented Coronary Artery Disease. Presented at: American College of Cardiology, 2010 Scientific Sessions, Late Breaking Clinical Trials Presentation; March 14, 2010; Atlanta, GA.
24. Drug Induced Diabetes – Insights for the Care of Patients at Risk. Presented at: Baptist Hospital Cardiovascular Conference Series; October 7, 2010; Miami, FL.
25. Supplements and OTC’s in the Cardiovascular Patient. Presented at: Core Curriculum for the Cardiovascular Clinician, Heart House; October 23, 2010; Washington, DC.

26. New Drugs That Will Change Your Practice. Presented at: American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 23, 2010; Washington, DC.
27. Hypertension: How Low Should We Really Go in the Patient with Diabetes? Presented at: American College of Cardiology, Scientific Sessions; April 4, 2011; New Orleans, LA.
28. Cardiovascular Implications of Dietary Supplements. Presented at: American College of Cardiology, 2012, Scientific Sessions; March 24-27, 2012; Chicago, IL.
29. BP: How Low Should We Go and How Do We Get There? Presented at: American College of Cardiology, 2012, Scientific Sessions; March 24-27, 2012; Chicago, IL.
30. CCA Team-Based Maintenance of Certification (Test Your Knowledge without a Test). Presented at: American College of Cardiology, 2012, Scientific Sessions; March 24-27, 2012; Chicago, IL.
31. Use of Generic Medications in the Management of Resistant Hypertension. Presented at: American College of Cardiology, 2012, Scientific Sessions; March 24-27, 2012; Chicago, IL.
32. Dietary Supplements: Use and Misuse. Presented at: American College of Cardiology, 2012, Scientific Sessions; March 24-27, 2012; Chicago, IL.
33. Supplements and OTC's in the Cardiovascular Patient. Presented at: 2012 Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician; October 2012; Orlando, FL.
34. New Drugs: Cardiovascular Pharmacology Update. Presented at: 2012 Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician; October 2012; Orlando, FL.
35. Anticoagulation and Antiarrythmics – An Update. Presented at: 2012 Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician; October 2012; Orlando, FL.
36. Pharmacometabolomics and Pharmacogenomics in Understanding Drug-Induced Adverse Responses. Presented at: Pharmacogenomics Research Network Fall 2012 Scientific Meeting; October 25, 2012; Seattle, WA.
37. Dietary Supplements: Use and Misuse. Presented at: 36th Annual Cardiology Update; February 2013; El Paso, TX.
38. Depression and Cardiac Patient: What the Cardiac Care Team Should Know to Safely Prescribe Anti-Depressants. Presented at: American College of Cardiology, 2013, Scientific Sessions; May 15-18, 2013; San Francisco, CA.
39. Depression and CAD: How to Manage the Sad Heart. Presented at: American College of Cardiology, 2013, Scientific Sessions; May 15-18, 2013; San Francisco, CA.
40. Cardiac Care Associate Maintenance of Certification: Guideline Case Studies for the Cardiac Care Team. Presented at: American College of Cardiology, 2013, Scientific Sessions; May 15-18, 2013; San Francisco, CA.
41. Generic Antihypertensive Drugs. Presented at: The American Society of Hypertension 2013 Scientific Annual Meeting, May 15-18, 2013; San Francisco, CA.
42. Treating Resistant Hypertension with Generic Drugs. Presented at: American Society of Hypertension 2013 Scientific Annual Meeting; May 15-18, 2013; San Francisco, CA.
43. A Metabolomic Approach into Addressing the Question Whether Multiple Drug-Induced Adverse Metabolic Effects Share a Common Mechanism. Presented at: American Heart Association 2013 Scientific Sessions; November 16-20, 2013; Dallas, TX.
44. Dietary Supplements: The Latest in Use and Abuse. Presented at: Central Florida Society of Health Systems Pharmacists; November 11, 2013; Orlando, FL.
45. Personalized Medicine and the Role of the Pharmacist. Presented at: 2014 Midwest Pharmacy Expo; February 7-9, 2014; Altoona, IA.
46. Cardiac Care Associate Maintenance of Certification: Guideline Case Studies for the Cardiac Care Team. Presented at: American College of Cardiology, 2014, Scientific Sessions; March 29-31, 2014; Washington, DC.

47. Drugs and Food – what do we really need to be concerned about? Presented at: Cardiovascular Fellows Conference, University of Florida; August 2014; Gainesville, FL.
48. Clinical Research Concepts, IRB Rules, and Regulations. Presented at: Master's in Public Health Orientation Program, University of Florida; August 2014; Gainesville, FL.
49. Hypertension – What's New in the Guidelines? Presented at: The Larry Lopez Cardiovascular Seminar: Redefining and Refining the Treatment Approaches to Cardiovascular Disease; October 2014; Orlando, FL.
50. Dyslipidemia – What's new in the Guidelines? Presented at: The Larry Lopez Cardiovascular Seminar: Redefining and Refining the Treatment Approaches to Cardiovascular Disease; October 2014; Orlando, FL.
51. Dietary Supplements and the CV Patient-Helpful or harmful? Presented at: The Larry Lopez Cardiovascular Seminar: Redefining and Refining the Treatment Approaches to Cardiovascular Disease; October 2014; Orlando, FL.
52. Nuts and Bolts of Cardiovascular Pharmacology. Presented at: American College of Cardiology – Core Curriculum for the Cardiovascular Clinician; October 14, 2014; National Harbor, MD.
53. Case Presentation: Which Drug For My Patient? Presented at: American College of Cardiology – Core Curriculum for the Cardiovascular Clinician; October 2014; National Harbor, MD.
54. Dietary Supplements in the CV Patient – Helpful or Harmful? Presented at: American College of Cardiology, March 2015 Scientific Sessions; March 14-16, 2015; San Diego, CA.
55. Case Studies From the Guidelines for Clinicians. Presented at: American College of Cardiology; March 2015 Scientific Sessions; March 14-16, 2015; San Diego, CA.
56. What Do I Want to be When I Grow Up? Independent Investigator. Presented at: American College of Cardiology, March 2015 Scientific Sessions; March 14-16, 2015; San Diego, CA.
57. Underappreciated Management Issues in Hypertension: Supplements and Interacting Substances That Can Impact Management. Presented at: American Society of Hypertension, May 2015 Scientific Sessions; May 16, 2015; New York, NY.
58. Supplements and OTC Drugs: Culprits to Consider When Evaluating Hypertension. Presented at: American Society of Hypertension, May 2015 Scientific Sessions; May 16, 2015; New York, NY.
59. Managing VTE: Matching Patient Need to Optimal Therapy. Preventive Care Nurses Association, 2015 Fall Lecture Series. Jacksonville, FL. October 24, 2015.
60. Contemporary Dietary Supplement Use: What is your Patient Taking and Why You Should Care? Presented at: New Cardiovascular Horizons; January 18, 2016; Orlando, FL.
61. Clinical Cases from the Guidelines for Clinicians. Presented at: American College of Cardiology, April 2016 Scientific Sessions; April 3, 2016; Chicago, IL.
62. Over-the-Counter Medications and Supplements: What the Cardiovascular Nurse Needs to Know. Presented at: Preventive Care Nurses Association, 2016 Annual Symposium; April 18, 2016; Orlando, FL.
63. Medication Adherence and the Role of Advanced Systems to Detect Adherence. Presented at: American Society of Hypertension, May Scientific Sessions; May 14, 2016; New York, NY.
64. *Keynote.* Precision Medicine: Where are we and Where are we Going? Presented at: American Society of Hypertension, Scientific Sessions; May 14, 2016; New York, NY.
65. Use of Pharmacometabolomics to Predict Statin Response – Are We Ready for Prime Time? Presented at: National Lipid Association; August 27, 2016; Amelia Island, FL.
66. An Evidence-based Approach to Dietary and Vitamin Supplements in Atherosclerotic Heart Disease. Presented at: American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; September 14, 2016; Washington, DC.

67. Practical Approach to Complex Pharmacological Needs: Polypharmacy, Drug/Drug Interactions – Case Based. Presented at: American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; September 14, 2016; Washington, DC.
68. A Pharmacist's Guide to PCSK9 Inhibitors: From Patient Selection to Pharmacoeconomics. Presented at: Medscape Pharmacy and Nursing Continuing Education; November 12, 2016; Chicago, IL.
69. Dietary Supplements: What's Hot, What's Not? Presented at: New Cardiovascular Horizons, Evolving Paradigms in Cardiovascular Care and Limb Preservation Symposium; March 4, 2017; Orlando, FL.
70. Top 10 Cardiac Medication Blunders. Presented at: American College of Cardiology, Scientific Sessions; March 18, 2017; Washington, DC.
71. To Anticoagulate or not to Anticoagulate: Balancing Benefits-risks in Complicated Patients: Case-based Learning with ARS. Presented at: American College of Cardiology, Scientific Sessions; March 19, 2017; Washington, DC.
72. Dietary Supplements – Does the Evidence Match the Hype? Presented at: Conemaugh 10th Annual Cardiovascular Symposium; May 6, 2017; Farmingtion, PA.
73. Understanding Medication Adherence: What Works. Presented at: American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 4, 2017; Washington, DC.
74. Dietary Supplements: What's Hot and What's Not. Presented at: American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 6, 2017; Washington, DC.
75. Improving Adherence to Medications Using Pharmacogenetics. Presented at: American Heart Association, Scientific Sessions; November 14, 2017; Anaheim, CA.
76. 2017 High Blood Pressure Guideline: What's New, What's Different? Presented at: Pharmacotherapy and Translational Research Seminar; January 19, 2018; Gainesville, FL.
77. Effective Medication Management in Older Adults with CVD. Presented at: Baptist Health South Florida, Cardiovascular Conference Series; February 15, 2018; Miami, FL.
78. Top 10 Cardiac Medication Blunders. Presented at: The American College of Cardiology, Scientific Session & Expo; March 11, 2018; Orlando, FL.
79. Therapeutic Targets for Endothelial and Microvascular Dysfunction: Old School and New Kids on the Block. Presented at: The American College of Cardiology, Scientific Session & Expo; March 12, 2018; Orlando, FL.
80. Getting Medications to Your Patients: How Best to Manage Prior Authorizations. Presented at: The American College of Cardiology; Scientific Session & Expo; March 12, 2018; Orlando, FL.
81. 2017 High Blood Pressure Guideline: What's New, What's Different? Presented at: North Central Florida Society of Health System Pharmacists; March 13, 2018; Gainesville, FL.
82. Medications and Blood Pressure. Presented at: UF IFAS Extension, Essentials of Blood Pressure Management Series; April 19, 2018; Gainesville, FL.
83. Medication Preauthorization: Tips and Tricks. Presented at: The American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 3, 2018; Washington, DC.
84. Dietary Supplements: What's Hot and What's Not. Presented at: The American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 3, 2018; Washington, DC.
85. Top 10 Cardiac Medication Blunders. Presented at: The American College of Cardiology, Scientific Session & Expo; March 17, 2019; New Orleans, LA.
86. PCSK9 inhibitors: Managing Hypercholesterolemia and Improving Patient Outcomes. Presented at: Asembia Specialty Pharmacy Summit 2019; April 29, 2019; Las Vegas, NV.
87. Precision Medicine in CV Disease—Where Are We and Where Are We Going? Presented at: Baptist Health South Florida; May 16, 2019; Miami, FL.

88. Implementing Pharmacogentics Clinically – Real World Experience and Lessons Learned. Presented at: 3rd Personalized Medicine Conference; May 30, 2019; Puerto Vallarta, Mexico.
89. UF Health Precision Medicine Program – Real World Preemptive Genotyping: The Future is Bright. Presented at: 12th Global Gator Symposium: New Developments in Clinical Pharmacy and Clinical Pharmacology; June 29, 2019; Reims, France.
90. Cannabis and e-Cigarettes – The Good, The Bad, and The Unknown. Presented at: The American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 3, 2019; Washington, DC.
91. Dietary Supplements – What should we be telling our patients? Presented at: The American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 5, 2019; Washington, DC.
92. Contemporary Dietary Supplement Use: What is Your Patient Taking and Why you Should Care? Presented at: New Cardiovascular Horizons, March 14, 2020, Orlando FL (Virtual).
93. CV Pharmacology – What's Hot for 2020? Presented at: The American College of Cardiology, Scientific Session & Expo; March 28, 2020; Chicago, IL (Virtual).
94. Screening and Evaluation – How to Identify The Appropriate Patient? Presented at: The American College of Cardiology, Scientific Session & Expo; March 29, 2020; Chicago, IL (Virtual).
95. Tackling the Supersized Epidemic of Cardio-Diabetes – Case 1 with ARS. Presented at: The American College of Cardiology, Scientific Session & Expo; March 29, 2020; Chicago, IL (Virtual).
96. Dietary Supplements – What should we be telling out patients (updates). Presented at: The American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 9, 2020; Washington, DC. (Virtual)
97. Cannabis and e-Cigarettes – The Good, The Bad, and The Unknown. Presented at: The American College of Cardiology, Core Curriculum for the Cardiovascular Clinician; October 10, 2020; Washington, DC. (Virtual)
98. CV Pharmacology: What's Hot for 2021? Presented at The American College of Cardiology, Scientific Session & Expo; May 15, 2021 (Virtual).
99. Supplements in Body Sculpting and Cardiovascular Disease. Presented at The American College of Cardiology, Scientific Session & Expo; May 17, 2021 (Virtual).
100. Supplement Use in CV Patients: What You Need To Know. Presented at the Cardiovascular Nursing Symposium; March 26, 2022, Las Vegas, Nevada.
101. CV Pharmacology: Cases From The Guidelines. Presented at: The American College of Cardiology, Scientific Sessions, April 2, 2022. Washington DC.
102. Medication Adherence: Patient and System Level Interventions to Improve Adherence. Presented at: The American College of Cardiology, Scientific Sessions, April 3, 2022. Washington DC.
103. Late Breaking Clinical Trials – Featured Clinical Research III Panelist/Discussant. Presented at: The American College of Cardiology, Scientific Sessions, April 4, 2022. Washington DC.
104. Tracking Electronic Health Record Data to Personalize Care. Presented at: Global Gator Meeting, June 3, 2022. Basel, Switzerland.
105. Realizing the Promise of Precision Medicine Using Real-World Evidence. Presented at: The Precision Medicine World Conference, June 30, 2022. Santa Clara, CA.